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ABSTRACT
Phosphonate analogs of peptides are important in biochemical research and potentially as
medicinal agents because of their ability to strongly inhibit both metallo and aspartyl
proteases.

Although a number of phosphorus-containing molecules were reported as

inhibitors

for

carboxypeptidase

A

(CPA,

there

have

been

only

a

few

thiophosphonopeptide inhibitors reported. There has been no investigation in which the
K\ values of a series of thiophosphonate inhibitors was compared to the analogous
phosphonates to probe the role the sulfur atom in inhibition. The goal o f this work is to
prepare phosphonopeptide inhibitors o f CPA and their thio-analogs so that this
comparison can be made. To accomplish this goal, we have utilized reduced phosphorus
[P(IH)J intermediates in an activation-coupling-oxidation protocol both on solid support
and in solution. In the solid-phase synthesis, only moderate yields of the protected amino
phosphonite coupling were achieved (40-70%).
obtained due to a stable

6

Also, no full-length products were

-membered cyclic oxazaphospholine formed during the

deblocking step of the resin-bound phosphonodipeptide.

In solution-phase synthesis,

activation in the presence o f base provides phosphonochloridite, which produces
oxaphosphazoles that are unreactive towards alcohols, which explains low yields.
Activation in the absence of base produces phosphonodichlorite, which does provide
phosphonopeptides, but lacking the ester protection.
An alternate route to CPA inhibitors that utilizes H-phosphonate esters as key
intermediates successful produced a phosphonopeptide CPA inhibitor and its thio-analog.
Preliminary enzyme assays found that phosphonopeptide peptide analog has a K, value of
1 0 1 4 M, and thio-analog has a K\ value o f about 10' 15 M.

This indicates that

XV
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thiophosphonate peptide analog is among the lowest values yet determined for protease
inhibition.
Several of desired targets could not be prepared because o f difficulties with Cterminal ester cleavage. Cleavage of methyl ester with thiolate led to decomposition for
peptides with a phosphonoalanine analog.
successful

for phosphonates,

but not

Allyl ester cleavage with palladium was
in

general

for thiophosphonates.

The

thiophosphonate sulfur' may react with the palladium catalyst to form a thioallyl ester,
which during the aqueous workup process is hydrolyzed to displace the sulfur moiety.

xvi
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CHAPTER 1. INTRODUCTION

1.1 Enzymes and Their Inhibitors
Enzymes are remarkably effective catalysts, responsible for the thousands o f coordinated
chemical reactions involved in biological processes of living systems.

Most enzyme

reactions take place very rapidly, as com pared with perhaps a year for some reactions in
the absence of enzymes. Indeed, most reactions in biological systems do not occur at
perceptible rates in the absence o f enzymes.

For example, carbonic anhydrase is an

enzyme that catalyzes the hydration o f carbon dioxide. Each molecule o f this enzyme
can hydrate 105 molecules of carbon dioxide per second. This catalyzed reaction is 107
times faster than the uncatalyzed one . 1
An enzyme accelerates the rate o f a reaction by lowering the free energy of
transition-state required for conversion o f reactants to products. The pathways of the
enzyme and non-enzyme reactions can in principle be described by a variety of paths that
resemble each other in energy." M ore accurately, the enzyme changes the pathway of the
reaction to a pathway having a lower free energy of activation, and provides an
alternative and more speedy reaction route (Fig. 1.1) . 3
The inhibition of enzymatic activity by specific small molecules and ions is
important because it serves as a m ajor control mechanism in biological systems.
Inhibitors are of great us pharmaceuticals and pesticides, since “an unnatural substrate
analog can block the action of a specific enzyme ” . 4 Such inhibitors are commonly used to
probe the chemical and conformational nature o f a substrate-binding site as part of an
effort to elucidate the enzyme’s catalytic mechanism and role in a metabolic process.

I
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Many inhibitors are substances that structurally resemble their enzym e’s substrates but
either do not react or react very slowly compared to substrates. These inhibitors can
compete directly with a normal substrate for an enzymatic-binding site and are known as
competitive inhibitors. One approach to designing competitive inhibitors is as a mimic of
a transition state of a reaction catalyzed by the enzyme.

The criteria for defining a

competitor inhibitor as a transition state analog of an enzyme are first, the inhibitor must
bind more tightly to the enzyme than does the substrate; second, the conformation of the
inhibitor is consistent with the structure o f the transition state postulated for the enzymecatalyzed reaction . 5

The approach to design of transition state analog inhibitors is

therefore to find stable molecules which resemble the reaction intermediates.

Uncatalyzed
reaction

\

Catalyzed
reaction

AG

Reactant

product
Reaction

coordinate

Fig. 1.1 Hypothetical catalysis with changing the pathway o f a reaction.
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1.2 Carboxypeptidase A and Its Inhibitors
Carboxypeptidase A (CPA) is a Zn2+-containing digestive enzyme that catalyzes the
hydrolysis of the carboxyl-terminal peptide bond in polypeptide chains.

Hydrolysis

occurs most readily if the carboxyl-terminal residue has an aromatic or a bulky aliphatic
side chain . 5 CPA is a protein with molecular weight o f 34,472 containing one zinc ion
bound to a single polypeptide chain of 307 amino acids. Important residues for catalysis
and binding are Glu 270, Arg 71, Arg 127, Asn 144, Arg 145, Tyr 248, and Zn2+. Tyr
248 is confirmed as a residue that is important for substrate binding, probably by
hydrogen bonding via its phenolic hydroxyl moiety. The enzyme contains a zinc atom
and other groups at its active site that induce rearrangements in the electronic distribution
of the substrate, thereby rendering it more susceptible to hydrolysis (Fig. 1.2.1 a ) . 6
Proteins and peptides are stable at neutral pH in the absence o f a protease because
water does not readily attack peptide bonds. A key catalytic task of carboxypeptidase A
is to activate water.

The mechanism for peptide hydrolysis by carboxypeptidase A

involves the three steps (Figure 1.2.1) : 6 (a) the precatalytic Michaelis complex with the
substrate carbonyl hydrogen bonded to Arg-127 allows for nucleophilic attack by a water
molecule promoted by zinc and assisted by Glu-270; (b) the tetrahedral intermediate
stabilized by both Zn2+ and Arg-127. In this complex, the zinc ion is five-coordinated,
and the Glu-270 is in a position to be hydrogen bonded to the tetrahedral intermediate; (c)
the final step is the transfer of a proton from the COOH group o f Glu-270 to the peptide
NH group. The peptide bond is concomitantly cleaved, and the reaction products diffuse
away from the active site.

3
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Fig. 1.2.1 Mechanism for the peptide hydrolysis by carboxypetidase A . 6
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Fig. 1.2.2 Examples o f early inhibitors of CPA.

Quite a few inhibitors for CPA have been reported. In the early days , 7 protein
chemists found an inhibitor, 3-phenylpropionic acid I, designed after a simple substrate
with the value o f an inhibition constant, Ku of 10' 3 M. Byers and Wolfenden 8 designed a
CPA inhibitor L-2-benzylsuccinic acid II which was a 1000-fold more potent than
inhibitor I (Ki =

6

x 10‘ 7 M). Then, Hofmann and Rottenberg5 prepared a transition state

analog, L-2-phosphoryloxy-3-phenylpropionic acid III, in which the carbon o f the
presumed tetrahedral intermediate (Fig. 1.2.1 b) was replaced by a phosphorus atom. The
inhibition constant K\ was improved to 1.4 x 10‘7M (Fig. 1.2.2).
Phosphonopeptides are peptide analogs in which an amide linkage has been
replaced with a phosphonate ester or phosphonamide. Phosphonate analogs of peptides
are important in biochemical research and potentially as medicinal agents because o f their
ability to strongly inhibit both metallo 9 ,1 0 and aspartyl proteases. 1 1 ,1 2

In addition,

phosphonate esters have been used as haptens for the production o f catalytic antibodies
possessing esterase activity (Scheme 1.2) . 13

The basis for this inhibitor action is

attributed to the similarity o f the tetrahedral phosphorus species to a presumed tetrahedral
intermediate arising from addition o f a zinc-bound water molecule to the substrate

5
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carbonyl group . 1 4 The insertion o f a phosphonate unit in the place of the scissile amide
bond of a substrate provides access to the additional binding interactions available within
the enzyme substrate complex as it approaches its transition-state conformation . 13

Catalytic
Antibody

0 2N
H 0.

H ?Vnh
v ^ K nH
2
O

R H

H

O

^

( ''V

nH

0

o

o

P roposed interm ediate

0

0

NH

H apten u sed to generate catalytic antibody

Scheme 1.2 Haptens for catalytic antibody production.

In the last decades, more research has been focused on transition state analog
inhibitors. In 1981, Bartlett et al . 16 synthesized a phosphonamidate dipeptide analog N[[[(benzyloxycarbonyl)amino]methyl]hydroxyphosphinyl]-L-phenylalanine,
salt as an inhibitor of CPA with K \ -

6

dilithium

x 10‘9 M. The molecule was a mimic o f the

substrate Z-GIy-L-Phe-OH with a tetrahedral phosphonamide moiety in the place o f the

6
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scissile peptide group. This indicated a new strategy for the design o f transition state
analogs of many enzymes. Also, phosphonate analogs have been prepared as inhibitors
of other Zn-proteases like thermolysin , 1 7 esterases such as leukocyte elastase , 1 8 as well as
haptens for the production of catalytic antibodies . 19
Since then, a number of phosphorus-containing inhibitors have been reported for
CPA with inhibition constants from

jliM

to fM range . 2 0 ,2 1 Phosphorus-containing

tripeptides, such as Z-Phe-Val\j/[P(0 2 ')]Phe-OH, were found to have K\ for inhibition of
CPA in the range of 10-27 fM. The investigation led to the determination o f what they
believed to be the lowest inhibition constant and slowest dissociation rate constant
measured for a low molecular weight enzyme inhibitor . 2 2

Table 1.1: Inhibition o f CPA by tripeptide phosphonates.

entry

inhibitor

1

Boc-AIa-Alay[P(0 2 )0]Ala-O H

^ (K P M V )

*off(10‘V )

tfi(pM )
646 000

Abbrev.: [BocAAp(0)A]
2

76 000

Z-Ala-Ala\|/[P(0 2 )0]A la-0H
Abbrev.: [ZAAp(0)A]

3

56 000

Z-Phe-Ala\|/[P(0 2 ')0]A la-0H
Abbrev.: [ZFAp(0)A]

4

24 500

Boc-T yr-Alai|/[P(0 2 ‘)0 ] Ala-OH
Abbrev.: [BocYAp(0)A ]

(table continued)

7
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5

Z-T yr-Ala\|f [P (0 2 ‘)O] Ala-OH

5

6000

6 .6

470 000

710

0.276

1 1 0 0 0

370

2 .0

800

4

2 .1

750

3

2 .2

2 2 0

I

2 .1

2.9

0 0 0

12 0 0 0

Abbrev.: [ZYAp(0 )A ]
6

Z-Ala-Glyi|/[P(0 2 *)0]Phe-0H
Abbrev.: [ZAGp(0)F ]

7

B oc-Tyr-V aly[P(0 2 ')0]A la-O H
Abbrev.: [BocYVp(0)A ]

8

Z-Ala-Phe\|/[P(0 2 ')0 ]P h e -0 H
Abbrev.: [ZAFp(0 )F ]

9

Z-Ala-Alai|A[P(02 ')0 ]P h e -0 H
Abbrev.: [ZAAp(0)F ]

1 0

Z-Phe-Ala\|f[P(0 2 )0 ]P h e -0 H
Abbrev.: [ZFAp(0)F ]

11

Z -Phe-V alv[P(0 2 -)0]P h e-0 H

0.014

Abbrev.: [ZFVp(0)F ]

1.3 Synthesis of Phosphonate and Thiophosphonate Peptide Analogs
Phosphonates and phosphonamides
phosphonochloridates

or

are

generally prepared by the reaction

phosphonodichloridates

with

alcohols

or amines.

of
The

chloridates are obtained from phosphonate diesters with phosphorus pentachloride , 2 3 - 2 4 or
by selective base hydrolysis o f phosphonate diesters to the monoesters followed by
reaction with thionyl chloride 2 5 ,2 6 ,2 7 o r oxalyl choride (scheme I.3.2 . ) . 2 8 '2 9 ,3 0 ' 31

In

addition, the synthesis o f phosphonopeptides by using BOP-phosphonate ester 3 2 and
modified Mitsunobu strategies 1 5 have been reported (Scheme 1.3.3).

8
R eproduced with perm ission of the copyright owner. Further reproduction prohibited without permission.

U Un
Phosphonochloridate

P h o sp h o n ate/ Mitsunobu
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Scheme 1.3.1 Retrosynthesis of phosphonopeptides.
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Scheme 1.3.2 Phosphonyl chloride condensation route to phosphonopeptides.
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Scheme 1.3.3 Mitsunobu condensation route to phosphonopeptides.

1. SOCI2/ c h 2c i 2
2. HCI. Gly-OAIlyl
Et3N /C H 2CI2
H
------------------------ F m oc-I

H
F m o c -N

H3CO

H2/Pd-C
EfOH/ H20

H3 CO

H A PN'P

HaCO Y

HA P P'

^

F m o c -N

A c-AlaN

_©

/ \

h3c o nn ^

Y

t

°

-V a l-V a l-A h x -O H

Scheme 1.3.4 Solid-phase synthesis o f phosphonopeptides from Fmocphosphonodipeptides.

In order to

improve

phosphonopeptide

synthesis,

several

groups

have

incorporated phosphonate amino acids into peptide chains by solid-phase methods. This
allows for use of excess reagents to help compensate for the slow kinetics and reduces the
need for purification. The advantages of a solid-phase synthesis, including high yields
and ease o f workup, would facilitate the synthesis of these important compounds. In
addition,

the

methodology

would

enable

the

construction

of

combinatorial

10

R eproduced with perm ission of the copyright owner. Further reproduction prohibited without permission.

peptidylposphonate libraries. In M affre-Lafon’s strategy , 2 3 the solid-phase synthesis of
two phosphonopeptides was carried out from an iV-Fmoc protected dipeptide precursor
with the P-N bond established. The target molecules were synthesized by coupling the
dipeptides to the N-terminal peptidyl resin using BOP/DIEA as reagents.

While this

method was effective for incorporation o f a phosphonamide linkage into a peptide, it
required that protected phosphonamide dipeptides first be prepared in solution (Scheme
1.3.4). Campbell and Bermak described solid-phase synthesis o f peptidylphosphonates
using a modified Mitsunobu coupling procedure , 3 3 in which the alcohol was condensed
with a methyl [N-(4-nitrophenethyloxycarbonyl)amino] alklyphosphonic acid, providing
the peptidylphosphonate with inversion o f configuration at the carbinol carbon.

The

betaine formed between the phosphine and dialkyl azodicarboxylate (DIAD) was basic
enough to cause removal of the Fmoc group, necessitating the use o f the more stable
protecting group 4-nitrophenethyloxycarbonyI (NPEOC).

The deprotection o f the

NPEOC group was accomplished with 5% DBU. Coupling yields o f greater than 90%
were obtained (Scheme 1.3.5). However, these reactions were highly dependent on steric
factors and couplings could take more than

12

hours to go to completion.

Subsequently, Campbell and coworkers reported the application o f their method
to the construction and screening o f a phosphonopeptide library and characterization of
its interactions with thermolysin, a well-studied zinc endopeptidase from Bacillus
thermoproteolyticus (Scheme 1.3.6 ) . 3 4
The library o f peptidylphosphonate sequences (Z-AP-°B -C -resin) was constructed
on non-cleavable resin. The C residue (P 2 ’ position) consisted o f 18 amino acids. Five
hydroxyl acids were used at the °B residue (P i’ position) and six aminoalkylphosphonic

tl
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acids at the Ap residue (Pi position).

This resulted in the generation of 540

peptidylphosphonates within the library.

The library was assayed for thermolysin

inhibition.

A fter each round o f screening, the most active pool was selected for

deconvolution.

Each subpool was then synthesized and assayed with the most active

mixtures then chosen for the next round o f screening.

1) pyperidine
2) HBTU, HOBt, DIEA +

Fmoc-NH-(peptide) ~ m --------------- 3 —

0

Fm“ " °

F m o c -O ^ A QH

R,

H

Ri

1) piperidine
2) tris(4-chlorophenyl)phosphine,
OIAD, DIEA

R2

H .A . O .A .
NPEOC— N
Pv v T 'N - ( p e p t i d e )

5 * 0
N P E O C -N

h

0

H3“ ' O

P -qh
' r.

fi,

H

1) 5% DBU
2) Fmoc-am ino acid,
HOBt, HBTU

R2
hA

O
. o^ J L

H2N—(peptide)— N
P, ^ r ^ N —(peptide)
H3CO x0
H

TFA, scavengers

R2

O

H2N—(peptide)— N ^ P ( ' ° ' V ^ S'N —(peptide)
HO O R
:,
H

Scheme 1.3.5 Solid-phase peptidylphosphonate synthesis cycle.
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Scheme 1.3.6 Synthesis o f inhibitor library.

Both phosphonic and thiophosphonic compounds can be considered as transition
state analog inhibitors due to the presence of a tetrahedrally hybridized phosphorus atom
at the position occupied by a trigonal planar carbon atom in the ground state of the
substrate. Nishino found N“-thiophospho-L-phenylalanyl-L-aIanylglycine amide IV (Kt
7.0 jiM) to be somewhat less potent than A^-phospho-L-phenylalanyl-L-alanylglycine
amide (Kt 2.6 (iM) in inhibiting the zinc metalloproteinase thermolysin . 3 3 Grobelny et al.

13
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reported that the sulfur analog, 2-benzyl-3-(0-ethylthiophosphono)propionic acid V (Fig.
1.3),

had

K\

a

of

2.1

pM,

ethylphosphono)propionic acid . 2 0

nearly

as

active

as

(2/?5)-2-benzyl-3-(0-

Although many methods exist to prepare simple

phosphonic acids and their derivatives, there are few techniques available for the
synthesis of highly functionalized phosphonates in which a sulfur is a substitute for one
or more of the oxygen atoms.

In Sampson’s paper, PhSH was used to prepare

thiophosphinyl compound VI as a suicide inhibitor of serine protease (Fig. 1.3) . 18 Martin
et al. reported a general procedure for the synthesis of esters o f phosphonodithioic
acids . 3 6 The method involved the reaction of the Grignard reagents with 2-chloro-1,3,2dithiaphospholane to give intermediate dithiophosphinates that were sulfurized using
elemental sulfur to provide the intermediate phosphonotrithioates. This reaction with a
variety of alcohols in the presence of DBU furnished the desired phosphonodithioates
(Scheme 1.3.7).

,S ^

Cl" v

R-MgX

/S '» I

------------------- "

©
s

s

R" P' ^

©

HOCH2CH2NMe3 O T s

> ' "1
S

Sa

S
►

DBU

r- p

@
-

o c h 2c h 2ni

^

Scheme 1.3.7 Synthesis o f esters of phosphonodithioic acids.
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Fig. 1.3 Thiophosphinyl inhibitors.

1.4. Goal o f the P ro ject

2

H X" \

R1

In

1
1a: R ^ B n , R2=/Pr, X =0; 1b: R 1=Bn, R2=/Pr, X=S;
1c: R 1=Bn, R2=Me, X =0; 1d: R 1=Bn, R2=Me, X=S;
1e: R 1=Me, R2=Me, X =0; 1f: R ’=Me, R2=Me, X=S;

Fig. 1.4 Target molecules.

In the 1980s, a number o f phosphorus-containing molecules were reported as inhibitors
for carboxypeptidase A. However, there have been only a few thiophosphonopeptide
inhibitors reported. There has been no investigation in which the AT* values of a series of
thiophosphonate inhibitors was compared to the analogous phosphonates to probe the

15
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role the sulfur atom

in

inhibition.

phosphonopeptides la , lc , le

W e therefore set out to prepare target

and thiophosphonopeptides lb , Id, If to make this

comparison (Fig. 1.4).
To accomplish this goal, we planned to em ploy a new method. Our laboratory
had previously developed preparing phosphonate, phosphonamide, thiophsphonate and
thiophosphonamide

peptide

analogs . 3 7

In

Y-acyl/alkoxylcarbonyl a-am ino-phosphonous

acid

this

approach

(Scheme

1.4),

esters

were

(H-phosphinate)

activated with dichlorotriphenylphosphorane (Ph. PCI,) to produce a highly reactive
trivalent species (phosphonochloridites, Scheme 1.4), which was used in the coupling
step with an alcohol or an amine (IDOL) to provide phosphonites.

In nucleoside

chemistry, it is known that nucleophilic displacement is much faster at P(III) than at P(V)
centers. 3 8 The resulting phosphonous [P(m )] tripeptide analogs were then oxidized or
sulfurized to the desired phosphonates (X = 0 , Y = 0 ), thiophosphonates (X = 0, Y=S),
phosphonamides (X=NH, Y = 0), and thiophosphonamides (X=NH, Y=S). Another goal
of this project is to develop general methodologies for the preparation of phosphonate
and thiophosphonate derivatives as CPA inhibitors, in which reduced phosphorus [P(III)]
intermediates are used as a way to potentially improve both the yield and accessibility of
these valuable peptide mimics. This would allow these important molecules to be more
readily available for biological and medicinal applications and, additionally, new
derivatives with sulfur ligands on phosphorus could be easily prepared. The remaine of
this dissertation is broken into three main parts: (1) Synthesis of phosphonate amino acids
suitable for use in the preparation o f CPA inhibitors 1 by the method in Scheme 1.4; (2)
Investigations into solid-phase and solution phase protocols for preparation o f 1 by the
activation-coupling-oxidation protocol and mechanistic studies into several aspects of

16
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this protocol, which explain low yields and side reactions; and (3) Development of an
alternate route to CPA inhibitors 1 that utilizes H-phosphonate esters as key
intermediates, which resulted in the first direct comparison o f the K* o f a known
phosphonopeptide CPA inhibitor with its thiophosphonate analog.

Ri
P h 3PCI2
P r o t- N
H

P -O R 2 —
H

P ro t-N

OR.

HXR.

am inophosphinate P(lll)

P ro t-N

j\y
P e p tid e -N
H

additional coupling

[0] or [S]

P^-XR3
OR2
X=N, O; Y =0, S

Schem e 1.4 Synthesis o f phosphonate and thiophosphonate esters and amides from
H-phosphinates by a one-pot procedure.
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CHAPTER 2. SYNTHESIS OF AMINOALKYLPHOSPHONOUS
ACIDS AND THEIR DERIVATIVES

According to the retrosynthetic analysis in scheme 1.3.1, aminoalkylphosphonous acids
and their derivatives were chosen as starting reagents to prepare the phosphonate and
thiophosphonate peptide analogs.

A general method to prepare functionalized

aminoalkyphosphonous acids was published by Baylis et al . /

9

and consisted o f the

addition of hypophosphorous acid (or derivatives) to /V-(diphenylmethyl)imines. Jiao et
al . 4 0

reported

an

one-pot

method

to

synthesize

differently

functionalized

aminoalkyphosphonous acids, using an addition of bis(trimethylsilyl) phosphonite to Ntritylalkanimines.

Both of these methods were employed in this work to prepare

aminoalkylphosphonous

acids.

9-Fluorenylmethoxycarbonyl

(Fmoc),

tert-

butoxycarbonyl group (Boc), benzyloxycarbonyl (Z) and triphenylmethyl (trityl) groups
were used to protect the N-terminus and various esters were prepared to block
phosphonite terminals.

2.1 Synthesis of l-Amino-2-methylpropanephosphonous Acid
l-Amino-2-methylpropanephosphonous acid

6

was the starting point for the synthesis of

the target molecules carboxypeptidase inhibitors Z-F-V-*P[(P0 2 > ( 0 )1 F-0 H and Z-F-V'F [(P 0S > (0)]F -0H . According to Haemers et al. , 4 0 a solution o f the protected imine 2
in chloroform was added to the in-situ-generated bis(trimethylsilyl) phosphonite 4 41 to
generate fully protected amino acid
hydrogen chloride provide,

6

.

Cleavage of the silyl and benzyl groups by

after removal of the solvent, aminophosphonous acid

6

,

which was isolated from an EtOH solution by addition of propylene oxide to scavenge
hydrogen chloride (yield 56%) (Scheme 2.1.1).

18
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N CPh;
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R. T./ 2 days
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propylene oxide

Scheme 2.1.1 Preparation o f l-amino-2-methyIpropanephosphonous acid (I).
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Scheme 2.1.2 Preparation of l-amino-2-methyIpropanephosphonous acid (II).
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Alternatively, reaction o f the diphenylmethylamine salt o f hypophosphorous acid
7 with aldehyde in refluxing EtOH, followed by treatment with 49% HBr to cleave
diphenylmethyl group gave the same product in 47% yield (Scheme 2.1.2 ) . 3 9
The yields of these tw o strategies were about the same. But since the latter one
takes less time, it was applied for synthesis o f compound 6 .

2.2 Synthesis of 1-Amino-ethylphosphonous Acid
Acetaldehyde

in

w ater

was

added

dropwise

to

a

refluxing

solution

of

diphenylmethylamine hydrochloride and 50% aqueous hypophosphorous acid to form
diphenylmethlyamino-ethylphosphonous acid. The product was treated with 18% HC1
and the solvent was evaporated. The residue was dissolved in EtOH and propylene oxide
was added dropwise to precipitate the aminophosphonous acid 9 (Scheme 2.2 )

o
®
^
P h 2CHNH3 Cl

IH 2 PO3 /H2 O

/ 9

_

2.A cetaldehyde/H 20
JL /,
-------------------------------- ► PhjHC-HN
P -O H
H

1. HCI (18% )
2.propylene oxide

I
//
P -O H
H

H2N

9

Scheme 2.2 Synthesis o f 1 -amino-ethylphosphonous acid.

2.3 Protection of Aminophosphonous Acids
W hen a chemical reaction is to be carried out selectively at one reactive site in a
multifunctional compound, other sites must be temporarily blocked. A protecting group
must fulfill a number o f requirements. It must react selectively in good yield to give a

20
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protected substrate that is stable to the projected reaction. The protecting group must be
selectively removed in good yield. The protecting group should form a derivative that
can easily be separated from side products associated with its formation or cleavage . 4 2
In the preparation of even the smallest peptide, it becomes obvious that certain
functional groups must be blocked 4 3 For example, to prepare dipeptide AAj-AAi, amino
acid AAj has to be coupled with amino acid AAi. In order to acylate the amino group of
the amino-component AA 2 , we have to activate the carboxyl group o f the AA[. The
activated carboxyl-component can acylate, however, not only the amino-component of
A A i, but also the amino group of AAi to yield AAj-AAj, instead o f the desired A A 1-AA 2 .
To prevent such unwanted by-products during peptide synthesis, Fmoc, Boc, trityl and Z
groups are used to block the amino side, while a variety of esters are utilized to protect
the carboxyl terminal.

i1
h 2n

" \ -

x

+

h 2n a

i 1 H jL
-x —

o

0

AA1

v

AAj

►

H2N ^ y N v f
0
Rt

x

AAj—AA j

Scheme 2.3 Formation o f by-product during peptide synthesis.

2.3.1. Protection of ^term inal of Aminophosphonous Acids
The 9-fluorenylmethoxycarbonyl (Fmoc) group is a contribution from the Carpino
laboratory to solution-phase peptide synthesis and has most successfully adapted to solidphase peptide synthesis of peptides . 4 4 The Fmoc group is exceptionally stable towards
acid, and can easily be removed in the presence o f mild base. The /V-protected Fm ocaminophosphonous acid 10 was obtained with 93% yields by addition o f 9-
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fluorenylmethyl chloroformate (Fmoc-Cl) to a solution of the

6

in water/dioxane mixture

at controlled pH (9-9.5) (Scheme 2.3.1) . 43

Dioxane/water
Fmoc-C!

+

H2N

Fmoc

Scheme 2.3.1.1 Fmoc protection of aminophosphonous acids.

The ferr-butoxycarbonyl group (Boc) remains one of the most frequently used
amino protecting groups. Being inert towards catalytic hydrogenolysis and extremely
resistant towards basic and nucleophilic reagents makes it an ideal orthogonal partner to
benzyl

esters

and

carbamates

methylpropylphosphonous acid
phenylacetonitrile

(Boc-ON)

6

used

in

peptide

was treated

2

synthesis . 4 6

l-Amino-2-

-(rm-butyloxycarbonyoxyimino)- 2 -

and triethylamine

in

DMF

to

form

butoxycarbonyl)amino]-2-methylpropylphosphonous acid 11 (Scheme 2.3.1.2.).

l-[JV-(r18

The benzyloxycarbonyl group (Z) fits well into a variety o f orthogonal protecting
group strategies since it can be cleaved by dissolving metal reduction, catalytic
hydrogenation,

and

aminophosphonous

strong
acid

acids (e.g.
12

was

HBr

in

acetic

prepared

acid).
by

Z-protected

dissolving

N-

(benzyloxycarbonyloxy)succinimide (Z-OSu) in dimethoxyethane and slowly adding I-
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amino-2 -methylpropylphosphonous
temperature . 4 7

acid

dissolved

The mixture was stirred overnight.

in

1 0

%

NajCC^

at

room

After w orking up, Z-protected

aminophosphonous acid 12 was obtained in 81% yield (Scheme 2.3.1.3).

P

H2N

A .

DMF

P -O H

+

B oc -O N

+

E t3N

P

------------- ^ B o c - N ^ > ~ O H

6 H

80 °C

H„

H
89%

ch3
H3C - C - 0 ~ C 0 —

Boc-

CH3

Schem e 2.3.1.2 Boc group protection o f aminophosphonous acid.

Jv.

P

/

^

\
jj

P

10% NaoCCK

H2N ^ P - O H

+

H2

Z-O Su

- 0 / ——
.
c h 3o c h 2c h 2o c h 3

Z -N

P "0 H
12

o

11

C -O -C —

z group

Schem e 2.3.1.3 Z group protection o f aminophosphonous acid.

In the activation and coupling o f carbamate-protected am ino acids, it is known the
carbamate carbonyl can participate by cyclizing onto the activated carboxylate carbonyl
(oxazalone formation ) . 4 8 Because o f the possibility for sim ilar participation of the
carbamate group in phosphinate amino acid activation and coupling (see Chapter 3 for
details), we wished to prepare amino protected derivatives that could not provide such
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anchiomeric participation. The triphenylmethyl (trityl) group is the one we chose here.
Others include a variety of sulfonyl groups , 4 9 and vinylogous imide protection like the
Dde 5 0 groups (Fig. 2.3). Compound 5 (prepared as in Scheme 2.1.1) was treated with
triethylammonium bicarbonate (TEAB) at room temperature to cleave selectively the
trimethylsilyl protection without removing the trityl group (Scheme 2.3.1.4). The TEAB
work-up allowed isolation o f the triethylammonium salt of the phosphinate 13. which
was organic soluble. Attempted isolation o f the free acid of 13 always led to significant
detritylation.

S—NH
Nbs

Bts

0

S es

Dde

Fig. 2.3 Non-participated protecting groups.

p S iM e 3
N ) S iM e 3

H

5

H O Et3NH

13

Scheme 2.3.1.4 Preparation o f trityl-protected aminophosphonous acid.
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Another

non-participating-protected

aminophosphonous

acid,

(phthalimidomethyl)phosphonous acid, was prepared by reaction o f bis(trimethylsilyl)
phosphonite 44 1 with (bromomethyl)phthalimide (Scheme 2.3.1.5)j0.

O

0

(Me3SiO)2PH

Scheme 2J.1.5 Preparation o f (phthalimidomethyl)phosphonous acid.

2.3.2 Protection of Phosphonous Terminal
The vast majority of phosphonous protecting groups merely serve to prevent a reaction
between the acidic phosphinate hydrogen and basic reagents. Consequently many of the
protecting groups used for phosphinate protection are identical to carboxylate protecting
groups in terms of introduction and cleavage.
The esterification of yV-protected aminophosphonous acids with alcohols in the
presence of

1,3-dicyclohexylcarbodiimide

(DCC)

and 4-(dimethylamino)pyridine

(DMAP) in dichloromethane (DCM ) 3 1 generated Fmoc-protected phosphonite esters.
Instead

of

DCC

and

DMAP,

l-[3-(dimethylamino)propyl]-3-ethylcarbodiimide

hydrochloride (EDC) can be used as coupling reagent. The mixture was stirred at room
temperature. The solution was diluted with EtOAc, washed with saturated KH 2 PO 4 ,
saturated NaHCC>3 , and brine, dried over Na 2 S 0 4, and evaporated to give peptide P(III)
analogs. The EDC method has a better workup procedure than that of DCC/DMAP
method. Use of the water-soluble carbodiimide proved to be important in facilitating the
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reaction workup, since silica gel chromatography could be avoided. The yields o f both
methods were about the same.

1 .R 2OH
2. DMAP
3. DCC

X
£
H'
14:
15:
16:
17:

H

h'

Xp

►
0H

H

° r EDC

R ^ F m o c ; R2=allyl
R ,=Fm oc; R2=Bn
R ^ B o c ; R2=/Bu
R ^ B o c ; R2=Bn

18:
19:
20:
21:
22:

R,=Z; R2=allyl
Ri=Z; R2=neopentyl
R 1=Z; R2=C H Ph2
Rt=Z; R2=(Bu
R ^trityl; R2=allyl

Scheme 2.3.2 Esterification of aminophosphonous acid and alcohols with DCC/DMAP.

2.4 Experimental Material
General Information
All reactions were performed in dry glassware under nitrogen or argon. Dichloromethane,
toluene and triethylamine were refluxing over CaH 2 and then distilling directly onto dry
molecular sieves. THF was refluxed over Na-benzophenone and distilled just prior to
use.

Anhydrous pyridine, methanol, benzyl alcohol and DM F were purchased from

Aldrich.

Dichlorotriphenylphosphorane was stored and proportioned in a strictly

anhydrous environment (dry argon box). Triethylammonium bicarbonate (TEAB) was
prepared by bubbling C 0 2 (dry ice) into a stirred suspension o f 87 mL water and 8.7 mL
triethylamine until all base was in solution (0.75 M) and the pH was at 8.5. NMR spectra
were collected on Bruker AC-200 and AC-250 FT NMR spectrometers, and were
referenced either to internal tetramethylsilane (*H) or external H 3 P 0 4 (3 tP). Coupling
constant (J) are given in Hz. Melting points were performed on a Fisher Meltemp. FAB
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MS was performed on a Finnigan MAT-900 double sector mass spectrometer equipped
with a PATRIC detector or a VG 7070E-HF using nitrobenzyl alcohol (NBA) or glycerol
as the matrix. Column chromatography procedures utilized silica gel (Merck, 230-400
mesh).

Tritylamine:52
It was prepared by stirring solid trityl chloride (30 g; 0.108 mol) with an excess o f conc.
Aqueous ammonia (28%, 150 ml; 2.22 mol) at room temperature for 2 days. The white
solid formed was collected by suction filtration, dissolved in 500 ml ether, washed with
10% NaHCC>3 (2 x 150 mL) and dried (Na 2 S 0 4). The solvent was evaporated and the
product was dried under high vacuum. Yield: 16.8 g (71%). mp 95 °C, (lit.

52

mp 96 °C)

'H NMR (250 MHz, CDCI3) 8 2,26 (br s, 2H, NH2), 7.26 (s, 15H, 3Ph).

A-Trityl-2-methylpropanimine (2):52
A mixture of tritylamine 1 (13.0 g; 0.05 mol), anhydrous EtOH (50 mL), and
isobutyraldehyde (4.0 g; 0.055 mol) was heated to reflux overnight. The solvent was
evaporated to give a practically pure product, which
benzene/hexanes. Yield: 13.6 g (82%). mp 89 °C, (lit .

52

was recrystallized

from

mp 88-90 °C). lH NMR (250

MHz, CDClj) 5 1.13 (d, 6 H, 2 C H 3), 2.61 (m, 1H, CH(CH3)2), 7.30 (m, 15H, 3 Ph).

Ammonium phosphinate (3):39
49% aqueous solution of hypophosphorous acid (13.2 g, 0.2 mol) was added to 0.88 M
aqueous ammonia (7.7 g, 0.22 mol) for 1 hr.

W ater was removed with rotary

evaporation. The white crystals were dried under high vacuum. Yield: 16.3 g (98%). 3lP
(101 MHz, CDC13) 8 4.35; mp 138 °C, (lit . 3 9 mp 138-139 °C).
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Bis(trimethylsilyl) phosphonite (4):41
This was prepared by heating together ammonium phosphinate 3 (2.5 g, 30 mmol),

8

mL

dried THF and 1,1,1,3,3,3-hexamethyldisilazane (4.8 g, 30 mmol) at 100-110 °C under
nitrogen for 5 hr in a 2-neck flask fitted with a septum and condenser. 3IP (1 0 1 MHz,
CDCI3 ) 8 137.6.

l-Amino-2-methylpropanephosphonous acid (6):39,40
Method A :40
THF (15 mL) was added from a syringe to the in situ generated bis(trimethylsilyl
phosphonite 4 (30 mmol) at 0 °C under N 2 and stirring was continued for 5 min.

A

solution of AT-trityl-2-methylpropanimine 2 (9.4 g, 30 mmol) in CHC13 was then gradually
injected at 0 °C and stirring for 12 hr gave the silylated, tritylated aminophosphinate 5
(31P (101 MHz) 5 152.5). The solvent was removed under reduced pressure, and the
residue was dissolved in 1 M HC1 in MeOH (50 mL) and refluxed for 15 min. The
solvent was again removed under reduced pressure. W ater (50 mL) was added and the
mixture was extracted with diethyl ether (3 x 20 ml). The aqueous layer was evaporated
under reduced pressure. The residue was dissolved in anhydrous EtOH (50 mL) and
treated with an excess of propylene oxide. The precipitated product was isolated by
suction, washed with EtOH and dried under vacuum. Yield: 2.46 g (57%). 'H NMR
(250 MHz, D 2 0 ) 1.09-1.13 ( 2 d, / = 7.0,

6

8

H, CH(CH3)2), 2,26 (m, 1H, CH(CH3)2), 2.95

(m, 1H, CH(C 3 H7)), 7.10 (d, / PH=535, IH, P-H); 3lP NMR (101 MHz, CDCl3)

8

14.1;

Analysis cal’d for C 4 H 1 2 N0 2 P: C, 35.02; H, 8.82; N, 10.23; found; C, 35.11; H, 8.70; N,
10.23.
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Method B :39
The diphenylmethylaminophosphonous acid
with an excess of 49% hydrobromic acid

(6 8

8

(14.5 g, 0.047 mol) was heated together

g) at 100 °C for 2 h until two distinct phases

had separated. The mixture was evaporated to dryness under reduced pressure and the
residue taken up in water. The aqueous solution was washed several times with ether to
remove diphenylmethyl bromide and then evaporated to dryness.

The residue was

dissolved in EtOH and propylene oxide added dropwise until precipitation started. The
solid was then filtered off, washed with EtOH and then ether, and dried. Yield: 6.4 g
(46%).

(Diphenylmethyl)ammonium hypophosphite (7) : 39
It was prepared by mixing equimolar amounts of diphenylmethylamine (18.3 g, 0.1 mol)
and anhydrous hypophosphorous acid (6 . 6 g, 0.1 mol) in EtOH (35 mL) for I h.

l*(Diphenylmethyl)amlnophosphonous acid (8):39
Equimolar amounts of diphenylmethylammonium hypophosphite 7 (0.1 mol) and
isobutyraldehyde were dissolved in absolute EtOH (20 mL), and the mixture was heated
to

reflux

for

3

h.

On

cooling

of

the

solution

a

precipitate

of

the

diphenylmethylaminophosphonous acid formed, and this was filtered off, washed with
EtOH, then ether, and dried. Yield: 14.5 g (48%).

1-Amino-ethanephosphonous acid (9):39
Acetaldehyde (4.4 g 0.1 mol) in water (25 mL) was added dropwise to a refluxing
solution of diphenylmethylamine hydrochloride (22 g, 0.1 mol) and 50% aqueous
hypophosphorous acid (13.2 g, 0.1 mol) in water (50 mL). Heating was continued for 2
h, after which the solution was cooled and the solid filtered off, washed with acetone, and
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dried to give 19.2 g (42%) o f a white solid. lH NMR

8

(250 MHz, D 2 0 ) 1.35-1.44 (2d,

7=7.5-15, 3H, CHCH3), 2,24 (m, 1H, CH(CH3)2), 6.96 (d, 7PH=530, 1H, P-H); 31P NMR
(101 MHz, D 2 0 )

8

21.2; FAB-MS m/e 108.4 (M+H)+.

l-[N-(9-Fluorenylmethoxycarbonyl)amino]-2-methylpropanephosphorous
(10):45

acid

Compound 6 (2.4 g, 17.5 mmol) was dissolved in water (17.5 mL), the pH o f the solution
was adjusted to 9.5 with 4 N NaOH and the mixture cooled to 4 °C. Fmoc-Cl (4.98 g
19.3 mmol) in dioxane (17.5 mL) was added. The mixture was stirred for

6

h while the

pH was maintained at 9-9.5 by periodic addition of 4 N NaOH. Then the mixture was
allowed to warm to room temperature and washed with ether (30 x 3 mL). The aqueous
solution was slowly added to a solution o f

6

N HC1 (70 mL) at 0 °C. The solid product

was collected by filtration and dried under vacuum. Yield: 5.8 g (92%). ‘H NMR (250
MHz, DMSO-t/e)

8

0.91-1.09 (2d, 6 H, 7=5.0, CH(CH3)2), 2.05 (m, 1 H, CH(CH3)2), 3.43

(m, 1H, CHCH(CH3)2), 4.31 (3H, C H fluorenyi + CH2), 6.72 (d, 7=475, PH), 7.36 (m,
2 H f l UOre n y i)»

7.74 (m,

2 H n u o re „ y i ) ,

7.89 (m,

2 H n u oren y i ) ;

3IP (250 MHz, DMSO-76)

8

28.0;

FAB-MS m/e 360.1 ((M+H)+); Analysis cal’d for C i 9 H 2 2 N0 4 P: C, 63.49; H, 6.17; N,
3.90; found: C, 63.05; H, 5.94; N, 4.04.

l-[iV-(/-Butoxycarbonyl)amino]-2-methylpropylphosphonous acid (11):
A mixture o f l-amino-2-methylpropyIphosphonous acid (2.55 g. 15 mmol), Boc-ON
(4.10 g, 16.6 mmol), TEA (3.13 mL, 22.2 mmol) and DMF (4.5 mL) was heated at 70 °C
for 12 h.

The triethylamine and DM F were removed under high vacuum and the oily

residue was diluted with water (65 mL), and the pH was adjusted to 7.5 by addition o f 4N
NaOH. The aqueous layer was washed with EtOAc (4 x 30 mL), then was acidified to
pH I with 12 N HC1 and extracted with CHC13. The combined CHC13 layers were dried
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over Na 2 SC>4 and concentrated in vacuo to form l-[/V-(/-butoxycarbonyl)amino]-2methylpropylphosphonous acid as yellow oil. Yield: 3.09 g, 89%. *H NMR (250 MHz,
CDCl3) 1.05 (m, 6 H, CH(CH3)2, 1.45 (s, 9H, COO-rBu), 2.22 (m, IH, CH(CH3)2), 3.79
(m, 'H , CH (C 3 H7» , 4.97 (d, 7 NH= 1 0 . 0 Hz, IH, NH), 7.04 (d, 7PN=560 Hz, 1H, P-H); 31P
NMR (101 MHz, CDC13) 28.6, 29.7 (7p .o h =1 1 1 Hz).

l-[iV-(Benzoxycarbonyl)amino]-2-methylpropylphosphonous acid (12):47
l-Amino-2-methylpropanephosphonous acid (0.14 g, 1 mmol) was dissolved in 10%
Na 2 C 0 3 (5 mL). Z-OSu (0.374 g, 1.5 mmol) in dimethoxyethane (3 mL) was slowly
added at room temperature. The mixture was stirred overnight, the dimethoxyethane
removed under reduced pressure, followed by adjusting pH to 7.5. The aqueous layer
was washed with ethyl acetate ( 5 x 3 mL). HC1 was used to adjust pH to 1.5. Then the
aqueous layer was extracted with chloroform ( 5 x 3 mL). The organic layer was dried
over M gS04, and evaporated to get a white solid product. Yield: 0.26 g, 96%. lH NMR
(250 MHz, CDC13)

8

0.89-1.10 (2d, 6 H, CH(CH3)2), 2.23 (m, IH, CH(CH3)2), 3.90 (m,

IH, CHCH(CH3)2), 5.36 (brs, IH, NH), 7.00 (d, 7=562, P-H); 31P (101 MHz, CDCI3) 5
30.9,31.7.

l-[(Trityl)amino]-2-methylpropanephosphonous acid triethylammonium salt(13):
The residue of intermediate 5 (1 mmol) was taken up in TEAB (1 M, 20 mL). The
mixture was stirred for 3 h. The solution was extracted with CH 2 C12 (3 x 20 mL), and the
organic phase was dried under reduced pressure. Yield: 2.3 g (95%).
MHz, CDC13)

8

'H NMR (250

0.83-1.27 (m, 6 H, 2CH3), 2.52 (m, IH, CH(CH3)2), 2.99 (2d, 7=7, IH,

CHPO), 6.48 (d, 7=525, IH, P-H), 7.22 (m, 15H, 3Ph), 7.57 (d, 7=7, IH , NH); 31P (101
MHz, CDC13) 8 27.5; FAB-MS (NBA) m/e 377.9 (M -H )\

31

Reproduced with perm ission of the copyright owner. Further reproduction prohibited without permission.

(Phthalimldomethyl)phosphonousacid :30
Ammonium phosphinate 3 (0.42 g, 5 mmol) and hexamethyldisilazane (1.11 ml, 5.3
mmol) were heated together at 100-110 °C under nitrogen for 2 h in a 3-neck flask fitted
with a septum and a condenser. The system was cooled to 0 °C and dry DCM (5 mL) was
injected, followed by (bromomethyl)phthalimide (1.26 g, 5.3 mmol). The reaction was
stirred overnight at room temperature, Filtered, and the solvent was removed in vacuo to
yield an oil.

This oil was dissolved in

8

mL methanol to achieve desilylation and

dissolution. This solution was crystallized overnight, filtered and the resulting solid was
dried in vacuum to give the phosphorous acid (0.932 g, 78%).

‘H NMR (250 MHz,

CDCI3 ) 5 5.52 (d, 2H, 7=10.75, C H 2), 7.13 (d, 7=567, P-H), 7.80 (m, 2H, Ph), 7.93 (m,
2H, Ph); 3lP (101 MHz, CDCI3) 5 21.7; FAB-MS (glycol) m/e 224.2 (M -H )\

O-Allyl
(14):

{l-[A-(9-fluorenylmethoxycarbonyl)amino]-2-methylpropane}phosphonite

To a solution of compound 9 (0.7 g. 1.95 mmol) and allyl alcohol (0.122 g, 2.1 mmol) in
dry CH 2 CI2 (3.5 mL) at room temperature under nitrogen, was added DMAP (0.135 mg,

1.1

mmol) and DCC (0.444 g, 2.15 mmol). After stirring at room temperature for 12 h,

the mixture was diluted with EtOAc (35 mL), filtered and washed and successively with

5% KHSO 4 , saturated NaHC 0

3

and saturated NaCl solution, dried over Na2S04 and

evaporated to give a white solid (0.62 g, 80%). *H NMR (250 MHz, CDC13) 8 0.89-1.10
( 2 d, 6H, CH(CH3)2), 2.25 (m, IH, CH(CH3)2), 3.92 (m, IH, CHCH(CH3)2), 4.24 (m, IH,

CHfiuorenyi), 4.45-4.64 (4H, CH2fiuorenyi + CH2CH=CH2), 5.00 (brs, IH, NH), 5.31 (m, 2 H,
CH2CH=CH2), 5.88 (m, IH, CH=CH2), 7.05 (d, 7=550, P-H), 7.34 (m, 4Hnuore„yi), 7.50
(m, 2Hfiuorenyi)> 7.68 (m, 2Hn„orenyi); 31P (101 MHz, DMSO-de) 8 31.9; FAB-MS (NBA)
m/e 400.1 (M+H)+.
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0-Benzyl {l-[Ar-(9-fluorenylmethoxycarbonyl)amino]-2-methyl}propanephosphonite
(IS ):5'
To a solution of compound 9 (1.4 g. 3.9 mmol) and benzyl alcohol (0.42 mL, 4.3 mmol)
in dry CH 2 C12 (5 mL) at room temperature under nitrogen, was added DMAP (48 mg,
0.39 mmol) and DCC (0.889 g, 4.3 mmol). After stirring at room temperature for 12 h,
the mixture was diluted with EtOAc (40 mL), filtered and washed and successively with
5% KHSO4 , saturated NaHCC>3 and saturated NaCl solution, dried over Na2S04 and
evaporated to give the ester. Yield: 1.52 g (87%). ’H NMR (250 MHz, CDCI3) 8 0.881 .2 1

(2 d, 6 H, CH(CH3)2), 2.19 (m, IH, CH(CH3)2), 3.36 (m, IH, CHCH(CH3)2), 4.34

(3H, CHfiuorenyi + CH2), 5.06 (m, 2H, CH 2 Ph), 5.10 (m, NH), 6.97 (d, 7=557, P-H), 7.31
(m, 4Hfluorenyl)> 7.72 (m, 2Hnuorenyl)< 7.85 (m, 2Hnuorenyl)>

P (101 MHz, DMSO-7fi) 8

33.4, 33.7; FAB-MS (NBA) m/e 450.2 (M+H)+; Analysis cal’d for C 26H28N 0 4 P: C,
69.46; H, 6.28; N, 3.12; found: C, 69.92; H, 5.98; N, 3.30.

0-f-ButyI {l-[iV-(r-butoxycarbonyl)amino]-2-methylpropane}phosphonite (1 6 ):st
Prepared

according

to

esterification

procedure

for

15

using

1-[N-(t-

butoxycarbonyl)amino]-2-methylpropylphosphonous acid (0.36 g, 1.5 mmol) and r-butyl
alcohol (0.17 ml, 1.7 mmol) to yield 16 (0.31 g, 72 %). lH NMR (250 MHz, CDC13)

8

0.99-1.09 (2d, 6 H, CH(CH3)2), 1.45 (s, 9H, 9H,.bulyl), 1.50 (s, 9H, 9H Boc), 2.21 (m, IH,
CH(CH3)2), 3.78 (m, IH, CHCH(CH3)2), 4.63 (brs, IH, NH ), 7.20 (d, 7=538, P-H ); 3,P
(101 MHz, CDC13) 8 24.2,24.9.

0-Benzyl {l-[/V-(f-butoxycarbonyl)amino]-2-methylpropane}phosphonite (1 7 ):SI
Prepared

according

to

esterification

procedure

for

15

using

l-[N-(r-

butoxycarbonyl)amino]-2-methylpropylphosphonous acid (83 mg, 0.35 mmol) and
benzyl ester (0.04 mL, 0.4 mmol) to yield 17 (80 mg, 77 %).

lH NMR (250 M Hz,
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CDCl3)

8

0.99-1.10 (2 d, 6 H, C H (CH 3)2), 1.43 (s, 9H, 9H Boc), 2.24 (m, IH, CH(CH 3 )2 ),

3.88 (m, IH , CHCH(CH3)2), 4.88 (d, IH , NH), 5.12 (m, 2H, C H 2 Ph), 7.03 (d, 7=550, PH); 3lP (101 MHz, CDC13) 5 31.2, 32.3 (7P^ = 1 1 1 Hz)..

O-Allyl {l-[Ar-(Benzoxycarbonyl)amino]-2-methyIpropane}phosphonite (18):
Prepared according to esterification procedure for 15 using EDC instead of DMAP/DCC,
starting from l-[/V-(benzoxycarbonyl)amino]-2-methylpropylphosphonous acid (0.1 g,
0.4 mmol) and allyl ester (0.3 mL, 0.44 mmol) to yield 18 (67 mg, 54 %). *H NMR (250
MHz, CDC13)

6

0.89-1.10 (2d, 6 H, C H (CH 3)2), 2.23 (m, IH, CH(CH3)2), 4.01 (m, IH,

CHCH(CH3)2), 4.52 (m, 4H, CH 2 C H =CH 2), 5.10 (s, 2H, CH 2 Ph), 5.27 (m, 2H,
CH 2 CH=CH2), 5.36 (br s, IH, NH), 5.88 (m, IH , CH=CH2), 7.05 (d, 7=542, P-H), 7.33
(s, 5H, Ph); 31P (101 MHz, CDC13) 5 34.1,34.3, 34.7, 35.1.

0-t-Butyl {l-[iV-(Benzoxycarbonyl)amino]-2-methylpropane}phosphonite (21 ):
Prepared according to esterification procedure for 15 using EDC instead of DMAP/DCC,
starting from l-[/V-(benzoxycarbonyl)amino]-2 -methylpropylphosphonous acid (0 . 1 g,
0.4 mmol) and r-butyl ester (33 mg, 0.44 mmol) to yield 21 (50 mg, 38 %). lH NMR
(250 MHz, C D C b) 50.89-1.10 (2d, 6 H, CH(CH3)2), 1.45 (s, 9H,.butyI), 2.23 (m, IH,
CH(CH3)2), 3.88 (m, IH , CHCH(CH3)2), 5.10 (s, 2H, CH 2 Ph), 5.38 (brs, IH, NH),
7.13(d, 7=542, P-H), 7.33 (s, 5H, Ph); 31P (101 MHz, CDC13) 5 23.5,23.9,24.4, 25.1.

O-Neopentyl {l-[/V-(Benzoxycarbonyl)amino]-2-methylpropane}phosphonite (19):
Prepared according to esterification procedure for 15 using EDC instead o f DMAP/DCC,
starting from l-[iV-(Benzoxycarbonyl)amino]-2-methylpropylphosphonous acid (0.1 g,
0.4 mmol) and neopentyl ester (39 mg, 0.44 mmol) to yield 19 (85 mg, 62 %). [H NMR
(250 MHz, CDCI 3 ) 5 0.92-1.10 (m, 15H, 9H f.butyl+CH(CH3)2), 1.88 (m, IH , CH(CH3)2),
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3.60-3.81 (m,
C H 2P h ) ,

2 H n e0 pe n t y i ) ,

7.04(d, 7=547,

4.04 (m, IH , C

P -H ),

H C H ( C H 3 ) 2) ,

7.34 (s, 5H, Ph);

31P

4.86 (brs, IH,

(101 MHz,

N H ),

C D C I 3) 8

5.12 (s, 2 H,

34.5,34.8, 35.2,

35.4.

O-Benzhydryl {l>[^V*(Benzoxycarbonyl)amlno]*2>methylpropane}phosphonite (20):
According to esterification procedure from

15

using EDC instead o f DMAP/DCC,

starting from l-[vV-(benzoxycarbonyI)amino]-2-methylpropylphosphonous acid (0.1 g,
0.4 mmol) and benzhydryl alcohol (81 mg, 0.44 mmol) to yield 20 (57 mg, 38 %). ‘H
NMR (250 MHz, CDC13) 5 0.88-1.10 (2d, 6 H, CH(CH3)2), 1.88 (m, IH, CH(CH3)2), 3.98
(m, IH, CHCH(CH3)2), 4.86 (brs, IH, NH), 5.09 (s, 2H, CH 2 Ph), 5.85 (m, IH, CHPh2),
7.28(2d, 7=405, P-H), 7.34 (s, 15H, 3Ph); 3lP (101 MHz, CDC13) 8 31.2, 31.7,32.6.

O-Allyl {l-[(Trityl)amino]-2 -methylpropane}phosphonite (22) : 31
Compound

13

(1.1 g, 2.9 mmol) and allyl alcohol (0.22 mL, 3.2 mmol) were dissolved in

CH 2 C12 (20 mL). DMAP (35 mg, 0.29 mmol) and then DCC (0.63 g, 3.0 mmol) were
added to the solution, and the mixture was stirred for 15 h, and diluted with EtOAc (35
mL), filtered and washed successively with 5% KHSO 4 , saturated N aH C 03. and NaCl
solutions, dried over Na 2 SC>4 and evaporated to give the crude phosphonous monoester,
which was purified by flash column chromatography (acetone-hexane 1:2, Et3N 0.5%).
Yield: 0.80 g (6 6 %). 'H NMR (250 MHz, CDC13)

8

0.83-1.37 (m, 6 H, 2CH3), 2.56 (m,

IH, CH(CH3)2), 2.81 (2d, IH, CHPO), 4.35 (m, 2H, CH 2 CH=CH2),

5.28 (m, 2H,

CH 2 CH=CH2), 5.85 (m, IH, CH=CH2), 7.24 (m, 15H, 3Ph); 3lP (101 MHz, CDC13)
40.0; FAB-MS (NBA) m/e 377.9 (M -H)\
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8

CHAPTER 3. SYNTHESIS OF PHOSPHONOPEPTIDE ANALOGS
BY USING ONE-POT PROCEDURE
3.1 Solid-Phase Synthesis
Methods for synthesizing peptides are divided into two categories: solution (classical)
and solid-phase (SPPS). The classical methods have evolved since the beginning o f the
20th century. The solid-phase procedure was first proposed by R. B. Merrifield in 1962,
with a full paper published in 1963.33 Solution synthesis retains value in large-scale
manufacturing, and for specialized laboratory applications.

However, the need to

optimized reaction conditions, yield, and purification procedures for essentially every
intermediate render the classical methods time consuming and

labor-intensive.

Consequently, most workers now requiring peptides for their research opt for the more
accessible solid-phase approach. The essential advantage o f SPPS is the ease with which
the blocked intermediates are separated from staring materials, reagents and most o f the
by-products. The separation processes are quick and simple, and can be machine-aided.
There is an enormous time and labor advantage over the corresponding operations in
solution chemistry which commonly involve techniques of solvent extraction, filtration,
evaporation, and crystalization. Retention of the resin-bound peptide in the same reaction
vessel at all the time also minimizes physical losses. Because soluble reagents can be so
easily removed by filtration, large excesses can be used, encouraging high efficiency in
the various chemical steps.
The concept o f SPPS has been outlined in Scheme 3.1. An N-protected amino acid,
containing appropriate side-chain protection if needed, is attached to a solid support. The
temporary N-protecting group is then removed and the amino acid-support is thoroughly
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washed with solvent. The next N-protected amino acid is then coupled to the amino acidsupport. The coupling may also be carried out using peptide fragments instead of single
amino acids, where the peptide fragment is N-terminal and side-chain protected. After
this reaction is completed, the dipeptide-support is washed with solvent.

The

deprotection / coupling cycle is repeated until the desired sequence o f amino acids is
generated. The peptide-support is cleaved to obtain the totally deblocked peptide.

H I M
H-C
-c -O
H
P ro t-N -CCH
-O H

+

HO—(su p p o rt

j

attach to su p p o rt

P ro t-N -C H - C - O — support
j

deprotection

H g N -C H -C -Q -( su p p o rt
|

couple

P ro t-N -C H -C -H N -C H -C -Q -{ su p p o rt
1

re p eat deprotection a n d couple

H N -C H -C -O — su p p o rt
1

|

C leave from su p p o rt

+ [su p p o rt

Scheme 3.1 General approach to solid-phase peptide synthesis.
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Ideally, the cleavage reagent also removes the amino acid side chain protecting
groups, which are stable to the deprotection reagent. These steps may be carried out as
either a batch process, where the support is filtered between each step, or as a continuous
flow process, where the support is always solvated during reagent exchange.

3.2 SPPS with Amino Phosphonites
Our laboratory has previously reported a method for synthesizing phosphonate esters
and phosphonamide peptide analogs . 3 7

In this scheme, the amino-phosphonous acid

esters were activated with dichlorotriphenylphosphorane (Ph 3PCl,) to produce a reactive
trivalent species, which was used in the coupling step with an alcohol or an amine
(HXRj) to provide phosphonites. The phosphorus [P(IH)] tripeptide analogs were then
oxidized or sulfurized to the desired phosphonates or phosphonamides (Scheme 1.4).
Given the success o f this method in solution, it was expected to be even more
efficient in solid-phase for the reactions just mentioned in section 3.1. Our strategy for
solid-phase synthesis of phosphonopeptide and thiophosphonopeptide CPA inhibitors is
shown in Scheme 3.2.1. Since effective CPA inhibitors have a free carboxylate at the
C-terminus, we will attach the first residue of the phosphonopeptide to a hydroxy resin.
That will generate a free acid after final cleavage. CPA best recognizes substrates and
inhibitors that have a hydrophobic aromatic group on the side chain (Phe, Trp) of the Cterminal residue. Additional, here we wish to make a phosphonate ester bond, so the first
residue is not an amino acid, but rather an a-hydroxyl acid, L-phenyllactic acid, Oprotected with a Fmoc moiety 23. After deblocking of the resin-bound Fmoc-carbonate

24, the free hydroxyl group on the resin will be coupled to phosphonochloridite 25
(generated according to our previously published procedure37) to give resin-bound
phosphonite 26. This is then immediately oxidized or sulfurized to give solid-supported
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phosphonate 27. It was expected that Fmoc-protected amino of 27 could be elaborated
by normal Fmoc peptide synthesis protocols to give phosphonopeptide after cleavage
from the support.

HO
Bn

VH

Fmoc-O'

o

Bn
J l . O
Fmoc-O'1 T

'^

20% piperidine/ DMF

Bn
^ L . 0

— H0

o
23

T
24

R1
F m o c - H N ^ P " CI
OR'

25
R1

O

Fmoc-HN^RC°V^O
'R0

X In

27

[O] or [S]
I
n
Jl
■
Fmoc-HN
P" V o
1h
OR' In
1.20% piperidine in DMF
26
2. Fmoc-Phe-OH/ HBTU/ HOBt
3.20% piperidine in DMF
4. Z-OSu, DIEA
5. TFA/ phenol/ triisopropylsilane

O R 1

0

Z-HN

<feX in

X = O o rS

Scheme 3.2.1 Solid-phase peptide synthesis phosphono and thiophosphono peptide
strategy.

Several subtler features of this strategy are worthy of comment. First, it is known that
phosphonate mono esters are generally stable to moderately strong acids like TFA , 3 4
whereas phosphonamides are highly acid labile . 12 Also, phosphonate ester protecting
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groups like methyl are cleaved by TFA as well . 3 5 Thus in picking our resin and our ester
group R’ on the phosphinate amino acid we chose one that were compatible with a
general SPPS strategy employing a TFA-labile support, and TFA labile “side-chain”
protection. In this case, since we needed a C-terminal acid, we chose the trifluoroacetic
acid

(TFA)-labile,

p-alkoxybenzyl

resin,

4-hydroxymethylphenoxyacetic

acid-

polyethyleneglycol-polystyrene (PAC-PEG-PS, Fig. 3.2.1). This PEG-PS graft resin has
several advantages over traditional PS resin as it solvates (“swells”) well in a wide range
of solvents and as a result has physical properties that tend improve peptide synthesis.
Furthermore, the choice of Fmoc strategy allows for simply spectrophotometic assays 5 4
for determining coupling yields by analysis o f the Fmoc group after cleavage (Scheme
3.2.2).

Scheme 3.2.2 Spectrophotometric assay5 4 for determining coupling yields by analysis o f
the Fmoc group. X =301 nm, e = 7800 M 'lcm*1.
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O
P A C -P E G -@

Fig. 3.2.1 Solid supports for peptide synthesis.

Our first target for solid-phase phosphonate peptide synthesis was the known
potent

CPA

inhibitor

phosphonotripetide

thiophosphonopeptide analog lb.

la

and

its

previously

unknown

Preparation of Fmoc-protected a-hydroxyl acid is

illustrated in Scheme 3.2.3. Esterification o f L-3-phenyllactic acid with methanol in the
presence of H 2 SO 4 led to ester L-3-phenyllactic acid methyl ester 28a.55 Protection of
hydroxyl functionality with Fmoc-Cl in pyridine 5 6 provided the compound 29, which
after acid hydrolysis gave the desired Fmoc-hydroxy acid 30.

Bn

Bn

1
HO

c h 3o h /h 2 s o 4
C 0 2H

T
HO

C 0 2CH;

Fmoc-Cl/ Pyridine

28a

Bn

Bn
HCI/ dioxane

Jk.

Fm oc-O

F m o c - O ^ C 0 2H

C 0 2CH3

29

30

Scheme 3.2.3 Preparation o f Fmoc-protected a-hydroxy acid.
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The results o f solid-phase phosphonopeptide synthesis strategy according to Scheme
3.2.1 are given below. First, loading Fmoc protected a-hydroxy acid 30 to the solid
support

was

accomplished

by

double

mesitylenesulfonyl)-3-nitro-l,2,4-triazole

coupling

(MSNT)

in

and

the

presence

1-methylimidazole

of

I-(2 -

(Melm)

(Scheme 3.2.4 ) . 5 7 The final loading was 0.17 mmol/g (87%).

Bn

T
F m o c -O

HO
C 0 2H —
Fmoc
M S N T /M elm

30

A°
23

0.
MSNT:

Bn

N ^ N°2
“N

A
Melm:

Scheme 3.2.4 Loading Fmoc-protected hydroxy acid to resin.

Next the aminophosphinate (10 equivalents, relative to resin-bound a-hydroxy acid),
which was activated by PI13 PCI2 (1.5 equivalents) in a solution of DCM was transferred
to an existing resin-bound oligomer containing alcoholic nucleophile 24 (in this case is
a-hydroxy acid) for 1 hr 45 minutes to provide resin-bound phosphonitopeptide 26.
After coupling, extra reagents were washed away by DCM ( 3 x 3 ml) and DMF ( 3 x 3
ml) and dried in vacuum.
Oxidation o f species 26 on-resin with an oxygen or sulfur electrophile provided
the desired phosphonate linkage. Thus, treating with the resin with r-BuOOH led to
(presumably) formation of resin-bound phosphonopeptide; adding Sg to P(m ) resin gave
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thiophosphonate peptide. The coupling yields of the phosphinate amino acid, determined
by Fmoc UV analysis54, were typically 40%-70%. After removal of the Fmoc group,
Fmoc-Phe-OH was immediately coupled with HATU/DIEA/DMF for 1 hour. 4 4
However, Fmoc analysis showed that no Fmoc group was incorporated.

Also, after

addition of Z-OSu and cleavage from the support, none o f the desired product was found
by mass spectral analysis or 31P NMR analysis.

20% piperidine

F m oc-H N ^ P '°V ^ O
OR'

h2n '

; p
•• O '

In

b ase

1. Z-Phe-OH /
HATU/DIEA
2. TFA / P henol/
Triisopropylsiiiane

X
*

OwOR'
HN

O

0

Bn

+

HO

in

H

q^ in

theory MS: 621

Scheme 3.2.5 Formation of 5-keto-3-isopropyl-6-benzyl-l,4,2-oxazaphospholine, a
phosphorus analog of a diketopiperazine (DKP).

Based on these results we hypothesized that the free amino group of the anchored
phosphonodipeptide was poised for a base-catalyzed intramolecular reaction on the
C-terminal carbonyl.

This is a common side-reaction in SPPS where dipeptides are

anchored as esters, caused by base deprotection (Fmoc) or neutralization, resulting in the
release of a cyclic diketopiperazine (DKP) from the solid support. 5 8 ,5 9 In our case, after
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removal o f the protecting group, a stable

6

-m embered cyclic 5-keto-3,6 -dialkyl- 1 ,4 ,2 -

oxazaphospholine was generated and ended up in the piperidine deblocking solution
(Scheme 3.2.5).

This was confirmed by evaporating the cleavage solution, and then

analyzed the solution by 3lP NMR.

Table 3.1 Cleavage methods
Cleavage Reagent

Cleavage Time
(min)

3lP (8 ) o f Solution
(ppm)

coupling yield of
Fmoc-Phe-OH (%)

Piperidine
50% in DMF

2 .5

9 .5 .2 6

52

50% in DMF

2

2 2.4.26

39

50% in DCM

2 ,3

1 7 .1 8 .5 .2 1 .2

47

20% in DCM

2, 8

22.7

47

20% in DMF

30 Sec x

20.6

44

8

TBAF (0.1 Ml
DMF

20

17,20.5, 25

54

DMF

3 ,7

17.20.5

43

DMF

2.2.5

20.5

45

THF

2,2

20.9.21.2

39

THF/DMF

2,2

20.6

37

In SPPS many methods have been developed to reduce D K P formation. Various
methods

have

been

tried,

including

different

cleavage

reagents

such

as

tetrabutylammonium fluoride (TBAF ) , 5 9 and a shorter time o f deprotection (Table 3.1).
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While some improvement in the coupling yields of the third residue (Fmoc-Phe-OH;
37-54%) were obtained with the modified Fmoc cleavage conditions (Table 3.2) of the
phosphonate dipeptide resins, still no desired products could be observed after addition of
the Z-group and cleavage from the support. Also, 3IP signals around 20 ppm consistent
with oxazaphospholine were found in all cleavage solutions, which means phosphorous
compounds were cleaved from the solid supports.

Fig. 3.2.2 2-Chlorotrityl resin.

Alternatively, 2-chlorotrityl resin (Fig. 3.2.2), in place of PAC resin, was chosen
to prevent “DKP” formation. This is a very acid-labile resin for preparing peptides and
partially protected peptide fragments. Due to extreme steric hindrance o f this resin, the
formation of piperazines at the dipeptide step is totally suppressed.60 Detachment of
protected

peptides

from

resin

can

be

accomplished

using

acid/trifluoroethanol/DCM at room temperature for short periods o f time.

acetic
The

attachment o f the first residue was carried out with 0.6 equivalents (use 2 equivalents o f
NovaSyn TGT 2-chlorotrityl resin) of the Fmoc-protected hydroxyl acid and 4
equivalents o f diisopropylethylamine stirred for 25 minutes.61 But probably due to the
high moisture sensitivity o f the resin, which hydrolyzed the Fmoc-protected hydroxy acid
from the resin, only 5% loading yield was obtained, according to Fmoc analysis. Thus
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both because of “DKP” formation, the low phosphinate coupling yields (40-70%), and
the lack of desired products, we decided to investigate a solution-phase approach to
synthesize CPA-inhibitor phosphonopeptide analogs.

3.3

Solution-Phase Synthesis of Phosphonopeptide Analogs
3.3.1

^
h 2n

2

Synthesis o f Phosphonite D ipeptide Analogs

O

pH
6 ,9

(n Bu)4N0H/M e0H/H2O
oh

?

"2"

Q

h

©
c r ki
/
N(nBu)4

3 1 ,3 2
Pivaloyl Chloride/Et3N

fj

1.31 o r 32
2. 0.5 N HCI

1.Allyl alcohol
2. DMAP/DCC

31: R1 = iPr; 32: R2 = CH3; 33: R 1 = iPr, R2 = Bn;
34: R1 = CH3, R2 = Bn; 35: R 1 = CH3, R2 = CH3:
36: R1 = iPr.

Scheme 3.3.1.1 Synthesis o f phosphonite dipeptide analogs.
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Since coupling dipeptide phosphonite analogs to hydroxy acid ester (in solution or solidphase) would avoid formation of “DKP” analogs, dipeptide phosphonite analogs were
prepared. The synthetic approach is described in Scheme 3.3.1.1. Z-group protected
amino

acids were activated by

trimethylacetyl chloride,62 then

coupled

with

tetrabutylammonium salts of 1-aminophosphonous acids 31 and 32, where were prepared
by mixing aminophosphonous acids 6

and 9 with an equivalent o f tetra-n-

butylammonium hydroxide.63 The purpose o f making the tetrabutylammonium salts 31
and 32 was to make the amino acid derivatives soluble in organic solvents like DCM.
After making dipeptide phosphonous acids, the Z-protected dipeptide analog 33 was
esterified with allyl alcohol in the presence of DCC/DMAP as for the carbamateprotected phosphonous amino acids (Section 3.3.2) to yield dipeptide phosphonite analog
36. (see Section 4.1 for synthesis of other peptide esters)
Allyl bromide was also used for protecting of hydroxy acid. Allyl bromide and
DIEA were added to a solution o f L-3-phenyllactic acid in CH3CN and allowed to sit
overnight to provide the hydroxy acid allyl ester 28b (Scheme 3.2.I.2.).

Bn
I

Bn
JL

Allyl brom ide/ DIEA

H O ^ X O g H ------------------------

x

H0

28b

Scheme 3.3.1.2 Synthesis o f L-phenyllactic acid allyl ester.
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3.3.2

Solution-Phase One-pot Synthesis Approach

The phosphonite dipeptide analog 36 was activated with Ph3PCl2 in the presence o f the
base to produce phosphonochloridite 37 (3,P NMR, Fig. 3.3.1), then coupled with a hydroxy acid ester 28b. 31P NM R showed clean conversion to phosphonite 38 (5 136).
Following the oxidation, the desired product 39 was formed (Scheme 3.3.2.1). After flash
chromatographic column purification, the tripeptide analog was obtained as shown by
FAB mass spectral analysis and 31P NMR.

O ^ v -f
\ r

~
36

N _

W /B a N

\ f

«■*'"

h

\ r ~

O-Allyl

\ »

37

OAllyl

31P : 178.1

A

Bn
HO

C 0 2Allyl,

Et3N ,1.5 h

^-N H

O
Bn

p - 0 ^ C 0 2Allyl
OAllyl

38
31P : 13 6 .7 B

t-BuOOH

O

1h

V -N H

O

xp h

.

J p -O

c o 2aii »i

OAllyl
39
31P: 2 3 .8 ,2 4 .2

C

FAB-MS m/e 663.2 (M+H)+

Scheme 3.3.2.1 One-pot synthesis procedure: adding base in the activation step.
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Fig. 3.3.1

31P NMR spectra: A, activated species phosphonochloridite 37, 8 = 178.1;
B, coupling product 38, 5 = 136.7; C, oxidation product 39 (before
purification), 8 = 23.5-24.4; triphenylphosphine oxide and its derivative, 8
= 27.3-35.8 in each spectrum.
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In applying this approach to synthesize phosphonoester peptides 39 we have
experienced low product yields (5-38%) that were the result of several side reactions
(Scheme 3.2.2.2, Fig. 3.3.2).

We believe that activation in the presence of the base

generated 37 (Fig. 3.3.2D), but now excess base can promote the cyclization of the
N-acyl/carbamoyl group onto the phosphorus, generating oxophosphazole derivative 40
(Fig. 3.3.2E), which was inactive towards coupling with weak nucleophiles like alcohols
(Scheme 3.3.2.2). This may be the reason that coupling of Fmoc aminophosphonites to
the resin-bound hydroxyl acid also produced low yields (40-70%) o f coupled products.
We believe that 31P NMR obtained after attempted coupling and oxidation is in fact the
oxophosphazole 41 and not a phosphonopeptide.

,

U

I

o

P h 3P C I2 / E t,N

0

1

( 0R

(n o R X N ) y

q

37(D)
31P N M R: 1 7 7 ,1 7 8 .8

E t3N

R

R1
tBuOOH
T
R2

)r ° l

OR

41(F)
31P N M R : 34.1

40 (E)
31P N M R: 1 9 4 .6

Scheme 3.3.2.2 Formation o f oxophosphazole derivative.
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Fig. 3.3.2

31P NMR spectra: D, activated species phosphonochloridite 37, 8 = 177.
178.8; E, formation o f cyclic phosphorus species 40, 8 = 194.6; F,
oxophosphazole derivative 41, 8 = 34.1; triphenylphosphine oxide and its
derivative, 8 = 27.9-35.1 in each spectrum.
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In an attempt to avoid side reactions caused by extra activation reagent and to
simplify purifcation o f phosphonopeptide products, resin-bound Ph3PCl3 was prepared
according to a modified literature procedure.64 The resin-bound Ph3P was swelled in
dichloromethane, and a solution of triphosgene was added whilst cooling to maintain the
temperature (Scheme 3.3.2.3). Gel-phase 3,P NMR showed dichlorphosphorane 42 (8
58.3 ppm).

Cl

'— '
42

Schem e 3.3.2.3 Preparation o f resin-bound dichlorophsphorane.

Due to the high sensitivity towards atmosphere, resin-bound Ph3PCl3 was
prepared and used in situ. A solution o f Fmoc aminophosphonite 15 and triethylamine in
DCM was injected into the flask containing resin-bound Ph3PCl3. The 3IP NMR signal of
the activated species was detected (5 192) ppm, as well as other by-products (5 218, 233,
234 ppm). However, after coupling with methyl phenyllactate (28a) and oxidation, the
desired dipeptide was detected (8 25 ppm) with another by-product (5 34 ppm), though
no improvement on the yield was achieved and the product was contaminated.
A less reactive activation reagent Ph3PF3 was also prepared65 and tested.
Triphenylphosphine, potassium hydrogen fluoride, and DMF were placed in a NMR tube
under

argon.

The

solution

was

cooled,

and

following

the

addition

of

diisopropylazodicarboxylate, placed in a sonic bath. 3>P NMR showed clean conversion
to difluorotriphenylphosphorane 43 (5 55.8 ppm). Also present was a small singlet at 5
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25.1, due to triphenylphosphine oxide (Scheme 3.3.2.4).

A solution o f Fmoc amino

phosphonite 15 and triethylamine in dichloromethane was injected into the NMR tube.
But none of the activated species was detected by 31P NMR. This means the PI1 3 PF 2 43 is
not strong enough to convert phosphonite to phosphonofluoridite.

1.K H F2, 0 ° C
2. DIAD

Ph3PF2

PPh3

43

Scheme 3.3.2.4 Synthesis of Ph 3 PFa.

In

1997,

Professor

Hirschmann

reported

that

treatment

of

the

phosphonochloridates with tertiary amines prior to addition o f the nucleophile resulted
in the formation of hitherto unrecognized phosphonylation agents, which they formulated
as phosphonyltrialkylammonium salts 45 . 6 6

The latter were more reactive than the

phosphonochloridates toward both alcohols and amines, affording improved yields o f
phosphonate esters and amides (Scheme 3.3.2.5.).

u
0
H ^OPNB
I
0
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N
B
<C0CI)* Fmoc—N
v^P^
:
OH

F m o .-H _
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Et3N
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O
" OPNB

c-CsHu
44

45

/In d o le
Indole
HO

CONH2

PNBOv ,0
0

CONH2

c-C6Hh

46

Scheme 3.3.2.S Formation o f phosphonyltrialkylammonium salts.
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Scheme 3.2.2.6 One-pot synthesis procedure: adding base after activation step.

Hypothesizing that such a mechanism maybe occuring with the P(III) amino
acids, we followed Hirschmann’s protocol by performing activation with PhsPCU without
base, then added base second (Scheme 3.3.2.6). jIP NMR indicated that the chemical
shift activated species 47 (3lP at 184 ppm, Fig. 3.3.3 H) was different than that formed in
presence o f base (Fig. 3.3.2 A). Also, the addition of base to 47 changed it to a species
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48 with 3IP at 164ppm (Fig. 3.3.3 I). The chemical shift o f the coupling product 49 (Fig.
3.3.3 J ) was different than that of the product 38, which is formed when base was added
in the activation step (Scheme 3.3.2.2).

Oxidation and sulfiirization o f 49 led to

phosphonate products 50 and 51 (Fig. 3.3.3 K) respectively. So this new strategy did
provide phosphonopeptide products, but they lacked the phosphonate ester protecting
group (e.g. allyl).
To discover if this side reaction was caused by excess Ph3 PCl2, a titration
experiment was performed.

When 0.5-0.75 equivalents of PhjPCli were added to

phosphinate dipeptide 5 2 ,31P NMR analysis showed chemical shift at 31 and 32 ppm, not
in the typical range for a phosphonochloridite (180-190 ppm) as was observed in
activations with slight excesses of Ph 3 PCl2 (e.g. 47, Scheme 3.2.2.6).

Addition of

hydoxyl ester to this gave a 3lP NMR peak (34 ppm) consistent with regeneration of the
starting phosphinate ester 52. Sulfurization provided a P(V) compound 54 which also
lacked addition of the hydroxyl acid ester (FAB MS). Only when at least l.l equiv.
activating reagent were added were 31P NMR signals (8 180-190 ppm) for presumed
phosphonochloridite obtained. When insufficient Ph3PC12 is added we propose that a
mixed phosphorus species 53 is formed (Scheme 3.3.2.7), which reacts with alcohol to
regenerate the phosphinate 52. Sulfurization of this (in the presence of TEA) leads to the
the thiophosphonic acid 54 (See Chapter 4.?? for further details on the sulfurization of
phosphinates). According to this experiment, less than one equivalent of Ph3PCl2 did not
lead to any loss of the phosphinate ester group.
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Scheme 33.2.7 Fewer equivalents of Ph3PCl2 caused no coupling of hydroxy acid ester.
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3IP NMR spectra: H, activated species 47, 8 = 182.0,184.1; I, reaction
with base to form 48, 8 = 164.4, 166.1; J , coupling product 49, 8 = 173.0,
173.6; K, sulfurization product, 51, 8 = 76.5, 77.1, 77.8, 78.1;
triphenylphosphine oxide, 8 = 27.5, 27.7; Ph3P=0«HCl, 8 = 40.2.
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An experiment was designed to study the reaction mechanism of the loss of
phosphinate ester.

Z-protected aminophosphonite neopentyl ester 19 (neopentyl ester

should be difficult to cleaved by either an SN1 or SN2 mechanism) was treated with 1.5
equiv. PI1 3 PCI 2 in the absence o f the base for 30 minutes.

This solution then was

analyzed by GC-MS (Fig. 3.3.4) which showed that the ester group was lost as neopentyl
chloride 59 during activation. W e have observed a similar same side reaction in our
synthesis of phosphonamide haptens . 6 7 2-Chloro-2-methylbutane 63 was not detected in
the reaction solution.

Also no neopentyl alcohol (tr = 3.1 min, data not shown) was

detected by GC-MS.
Based on these results we believe activation of phosphinates (e.g., 19, 36, etc.) in
the absence or presence of the base does form phosphonochloridites 56 (Scheme 3.3.2.8),
but in the absence o f base, most likely the HC1 generated in the reaction cleaves off the
alkyl phosphonate ester bond to give phosphonodichloridite 64. There are three possible
paths to generate phosphonodichloridite 64 after phosphorus is protonated. In Path A,
chloride attack on the P-protonated species 57a promotes an SN2-like reaction to break
the oxygen-carbon bond in which neopentyl chloride 59 is generated as a co-product. In
Path B, following the S sl-lik e cleavage of oxygen-carbon bond to generate a unstable
primary carbon cation, a

1 ,2

methyl migration reaction would yield a stable tertiary

carbon cation 62, and 2-chloro-2-methylbutane 63 would be formed. In Path C, transfer
of the proton to the ester oxygen to form 57b followed by attach o f chloride on the
phosphorus would produce phosphonodichloridite 64 directly plus neopently alcohol.
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The fact that no rearranged 2-chloro-2-methyl butane is observed seems to eliminate Path
B. The absence of neopentyl alcohol seems to discount Path C, however, it is known that
Pl^PCh can convert alcohols to chlorides. Thus, the mechanism is either Path A, an Sn2like cleavage to form neopentyl chloride (59), or Path C whereby neopentyl alcohol is
initially formed and then subsequently converted to neopentyl chloride (59) by excess
Ph 3 PCl2.
Also, when the base (1.2 equiv.) and nucleophile were added after activation,
double coupling o f the incoming alcohol nucleophile to the phosphorus center was
observed as FAB-MS m /e 811.8 (M+H)+ for Z-Phe-VaIvF[P(0)(0Phe-0M e)0]Phe-0M e
and 827.6 (M+H)+ for Z-Phe-ValxF[P(S)(OPheOMe)0]Phe-OMe.
In Professor Hirschmann’s report , 6 6 the base was considered to be a nucleophile.
It attacked on phosphorus center to provide an intermediate, phosphonylammonium salt,
which was highly reactive phosphonylating agent, affording higher yields o f phosphonate
ester and amide. However, instead o f TEA, when the non-nucleophilic base 2,6-di-tbutyl-4-methyl-pyridine was used in our reaction, we found hydroxyl acid ester was able
to couple to the phosphinate activated species. This seemed to indicated that formation
of phosphonitylammonium salt is not necessary for the condensation and the base may
not be a nucleophile in our strategy.
In order to investigate whether or not the base played role of forming reactive
intermediate B or C as was the case in P(V) chemistry reported by Hirschmann 6 6
(Scheme 3.3.2.5), we developed a method in which solid-supported DIEA resins were
used in the place o f TEA (Scheme 3.3.2.9).

DIEA-PS is a highly loaded tertiary amine

base that is a resin-bound equivalent o f DIEA.

DIEA-PS is useful in applications
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requiring a tertiary amine base, where the resin-bound ammonium salt products are
readily separated by nitration.

So if the base reaction is an nucleophilic attachment,

detecting31P NMR peaks on the solid support would prove this.

F m o c-N

P -0B n

Fmoc—N

\

Cl

X

or

Fmoc-N
H

P
Cl

DIEA-Resin

B

or

Fmoc

y /\

H S ' bH
31

D

C 02Me

P : 8 7 ,8 9 ; FAB m /e 5 5 2 .5 (M -H )'

Scheme 3.3.2.9 DIEA resins as potential nucleophile in activation o f phosphonites.

Fmoc-aminophosphonous acid ester 15 was activated by Ph 3 PCl 2 and the solution
was transferred to a container holding DIEA-PS (Scheme 3.3.2.9). The resin and solution
were separated by filtration and both phases were analyzed by 3iP NM R. On the solid
support, no 3IP NMR signals were detected (except for some residual Ph 3 P = 0 precipitate
from the activation reaction); in the solution phase, only 3lP NMR peaks consistent with
A or B were found

(8

= 192). Next hydroxyl acid methyl ester 28a and then Sg were
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added successively.

3lP NMR analysis o f the solution indicated the presence of

thiophosphonate dipeptide product (8=87-89), which was also confirmed by FAB-MS.
Since the activated aminophosphonate A or D did not bond to the DIEA-resin to form B
or C, we conclude that generation o f phosphonitylalkylammonium salts does not occur in
our synthetic approach.
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Schem e 3.4 Side reactions in phosphonous ester activation with PI1 3 PCI2 .
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3.4 Summary
Based on these observations we propose pathways (Scheme 3.4) which account for
successful coupling (Path A), the lack of coupling when phosphonous acids are activated
in the presence of base (Path B), and the side reaction which removes the phosphonite
ester protection (Path C).

Thus, activation in the presence o f base provides

phosphonochloridite 64, but there is delicate balance between Path A, which leads to
coupling products, and Path B which produces oxaphosphazoles 70 that are unreactive
towards alcohols. This balance is driven to the cyclic derivative 70 by excess base, but
even when limiting base is present, often little or no coupling products are formed. Thus,
the exact nature of the amine and ester protecting groups and the side chain group on the
phosphinate amino acid are also likely affecting the balance between 64 and 70.

A

similar cyclization can take place with phosphonodichloridite 65 to generate chlorooxophosphazole

6 6

(Path C), which can couple with alcohols (R’OH, in this case

phenyllactate esters) to generate 67. Oxidation or sulfurization of 67 followed by ring
opening (presumably in the aqueous work-up) leads to phosphonate monoesters
lacking the original protection group (Path C).

6 8

When there is less base present (-1

equiv.) phosphonochloridite 65 doesn’t cylcize, but rather can couple to 2 equiv. of
alcohol nucleophile (R ’OH) to produce phosphonite, again lacking the original
phosphonate ester protection group (Path D).

Oxidation o r sufurization provide the

thiophosphonate or phosphonate “double” esters 69 (Observed by FAB-MS and H- and
3

lP-NMR).
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3.4

Experimental Material

Technical information
Anhydrous DCM, pyridine, methanol, benzyl alcohol and DMF were purchased
from Aldrich. Dichlorotriphenylphosphorane was stored and proportioned in a strictly
anhydrous environment (dry argon box). DMF and 20% piperidine solution in DM F
were obtained from Perseptive Biosystems. Fmoc amino acids were purchased from
Advanced Chemtech. PAC-PEG-PS (0.15 mmol/g) resins were obtained from Perseptive
Biosystems. Ultraviolet-visible spectra were performed on an AVIV 14DS UV-VIS-IR
spectrophotometer.

Determination of coupling yield on Fmoc amino acid resin :54
The substitution level of Fmoc amino acid resins is determined by quantitative
spectrophonometric monitoring following piperidine deblocking.
resins (4 to

8

Fmoc amino acyl

mg) are shaken or stirred in piperidine-DMF (3:7) (0.5 mL) for 30 minutes,

following which MeOH (6.5 mL) is added, and the resin is allowed to settle.
resultant fulvene-piperdine adduct has UV absorption maxima at 267 nm
cm '1), 290 nm

(e

= 5800 M 'cm '1), and 301 nm

(e

(e

The

= 17,500 M ' 1

= 7800M 'lcm '1). For reference, a

piperidine-DMF-MeOH solution (0.3:0.7:39) is prepared. Spectrophotometric analysis is
typically carried out at 301 nm, with comparison to a free Fmoc amino acid o f known
concentration treated under identical conditions. The substitution level (mmol/g) = (A 3 0 1
x 106 mol/mol x 0.007 L/7800 M 'cm " 1 x 1 cm x mg o f resin).

L-Phenyllactic acid, methyl ester (28a):
L-3-Phenyllactic acid (1.65 g, 9.9 mmol) was dissolved in CH 1 CI2 (12 mL) with methanol
(1.2 mL) and 98% sulfuric acid (0.03 mL). The mixture was heated to reflux for 18 h.
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Then the reaction mixture was washed with water, saturated N aH C 0 3 and saturated
NaCl. The organic layer was dried under reduced pressure to yield product. Yield: 1.59
( 8 8 %); mp 47-49 °C. lH NMR (250 M Hz, CDC13)

8

2.68 (d, 7=5, OH), 3.05 (m, 2H,

C H 2 Ph), 3.78 (s, 3H, C H 3), 4.46 (m, 1H, C H ), 7.24 (m, 5H, Ph); Analysis cal’d for
C i0 H, 2 NO3: C, 66.64; H, 6.72; found: C, 66.81; H, 6.77.

L-3-PhenyIlactic acid, allyl ester (28b):
L-3-Phenyllactic acid (1.66 g, 10 mmol) was dissolved in CH 3CN (25 mL), allyl bromide
(2.6 mL, 30 mmol) and DIEA (2.6 ml, 15 mmol) was added successively. The mixture
was stirred for 12 h at room temperature, diluted with EtOAc (30 mL), washed with
water and dried under reduced pressure. Yield: 2.02 g (98%). 'H NMR (200 MHz,
CDC13) 8 3.07 (m, 2H, C H 2 Ph), 4.46 (t, J=2, 1H, CH), 4.70 (d, 7=2, 2H, CH=CH2), 5.31,
(m, 2H, C H 2 CH=CH2), 5.89 (m, 1H, C H =CH 2), 7.24 (m, 5H, Ph).

l-[-(9-Fluorenylmethoxycarbonyl)hydroxy]-3-phenyllactic acid, methyl ester (29):
L-3-Phenyllactic acid, methyl ester (1.48 g, 8.2 mmol) was dissolved in pyridine (50 mL)
at 0 °C. Fmoc-CI (2.6 g, 9.9 mmol) was added and the mixture was stirred for 2 h.
Solvent was evaporated under reduced pressure and the residue was dissolved in EtOAc,
then washed with 0.5 N HCI.

The organic layer was dried to give l-[-(9-

fluorenylmethoxycarbonyI)hydroxy]-3-phenylIactic acid, methyl ester which can be used
directly in next step.

l-[-(9-Fluorenylmethoxycarbonyl)hydroxy]-3-phenyllactic acid (30):
It was prepared by adding 1 N HCI (20 mL) and dioxane (20 mL) to l-[-(9fluorenylmethoxycarbonyl)hydroxy]-3-phenyllactic acid, methyl ester (8.2 mmol). The
mixture was heated to reflux for 5 h, then washed with saturated N aH C 0 3 and hexanes.
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The aqueous layer was extracted with CHCI3 (3 x 30 mL). The organic layer was washed
with

0.5 N

HCI,

then dried

under reduced pressure

to

give

pure

l-[-(9-

fluorenylmethoxycarbonyI)hydroxy]-3-phenyllactic acid. Yield: 1.75 g (55%); ‘H NMR

(250 MHz, CDCI3 ) 8 3.29 (m, 2H, CH 2 Ph), 4.24 (m, 3H, CHnuorcnyi+CH^orenyi), 5.23 (m,
1

H, CH), 7.35 (m, 9H, Ph+4Hnu0 renyi), 7.50 (m, 2Hnu0 renyi), 7.76 (m, 2Hnu0 renyi); Analysis

cal’d for C 2 4 H 2 0 O5: C, 74.21; H, 5.19; found: C, 74.43; H, 5.16.
Loading Fm oc hydroxy acid to PAC-PEG -PS resin (23):S7
Fmoc-protected hydroxyl acid 25 (44.2 mg, 0.11 mmol) and l-methylimidazole (Melm, 7
mg, 0.08 mmol) were dissolved in CH 2 C12 (1.5 mL).

Under N2, the solution was

transferred with a syringe to a flask containing the l-(2-mesitylenesulfonyl)-3-nitro1,2,4-triazole (MSNT, 31 mg, 0.11 mmol). The mixture was immediately added to PACPEG-PS resins (200 mg, 0.19 mmol/g). After coupling 2 h, reactants were washed out
with DCM ( 3 x 3 mL), DMF ( 3 x 3 mL) and DCM again ( 3 x 3 mL). The resins were
dried in high vacuum.

Fmoc UV analysis was performed on 4-8 mg resins.

If the

coupling yield was low, a second loading was carried out under the same condition.
Yield: 87%. The loaded resins were capped with 0.2 M acetic anhydride in 0.28 M DIEA
in DMF for 45 min. After removal of the Fmoc group with 20% piperidine solution in
DM F ( 2 x 2 mL) for 15 min, the resins were washed with DCM ( 3 x 3 mL), DMF ( 3 x 3
mL), DCM ( 3 x 3 mL), and dried under high vacuum.
A ttem pted SPPS o f carboxypeptidase inh ib ito r Z-Phe-V al'F[(PO O Bn)0]-Phe-O H :
At room temperature, a solution of Ph 3 PCl 2 (0.34 g, 42 equivalents) in DCM was added
dropwise to a solution o f protected amino phosphorous acid ester 15 (0.13 g, 12
equivalents) and TEA (0.02 mL, 20 equivalents) in DCM with stirring. 30 minutes later,
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the activated P(III) compound solution was added to the hydroxy-acid-loaded resin (200
mg,

6 8

% loaded), followed by adding TEA (0.18 mL, 40 equivalents) under argon and

left for 1 h. The resins were washed with anhydrous CH 2 CI2 ( 3 x 3 mL) and DMF ( 3 x 3
mL), and treated with r-BuOOH (0.12 mL, 15 equivalents) for 1 h. Then resins were
washed with DCM, DMF and DCM, dried in vacuum. The coupling yield (71%) was
determined by Fmoc UV analysis. The protected phosphonopeptide-bound resins were
treated with 20% piperidine in DMF to deprotect. Fmoc-protected phenylalanine ( 28
mg, 3 equivalents) and HATU (27 mg, 3 equivalents) were dissolved in 0.28 M DIEA
(0.45 mL, 5.3 equivalents) in DMF. Then the mixture was added to resin for 2h. Fmoc
group was removed again and the resins were treated with solution o f Z-OSu (67 mg. 5
equivalents) in 0.3 M DIEA (, 15 equivalents) in DMF (2.8 mL) for 1.5 h. The putative
phosphonopeptide analog was cleaved from the support by addition of a mixture of

8 8

%

TFA, 5% phenol, 5% water, 2% triisopropylsilane for 2h. The resins were washed with
CH 2 CI2 and the solvent removed. W ater was added and the aqueous solution was washed
with ether 3 times. The aqueous layer was evaporated in a centrifugal evaporator and
analyzed by 3lP NMR and FABMS.

Attempted SPPS of carboxypeptldase inhibitor Z-Phe-Val'P[(PSOBn)0]-Phe-OH:
Coupling of protected phosphonous amino acid ester was performed according procedure
described above. Instead o f /-BuOOH, Sg (15 eq) in DCM was used for sulfurization.
Coupling yield was 92%.

l-Amino-2-methylpropanephosphonous acid, tetrabutylammonium salt (31):
l-Amino-2-methyIpropanephosphonous acid

6

(0.69 g, 5 mmol) was dissolved in

M eO H /ltO (16.5 mL, 1:1). The solution was treated with (n-Bu)4 NOH (3.1 mL, 4.75
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mmol) and the mixture was stirring for 2h at room temperature.

The solvent was

evaporated under reduced pressure to give clear oily product. Yield: 1.95 g (100%). lH
NMR (250 MHz, CDC13)

8

0.97 (m, 18H, CH 3 (n-Bu)4), 1.42 (m, 8 H, C H 2 (n-Bu)4). 1.60

(m, 8 H, CH 2 (/i-Bu)4), 2.09 (m, 1H, CH(CH3)2), 2.26 (m, 1H, CH), 3.28 (t, 8 H, C H 2 (nB u )4),

7.00 (d, 7=465, 1H, P-H), 3lP (101 MHz, CDC!3) 5 30.3.

1-Amino-ethanephosphonous acid, tetrabutyl ammonium salt (32):
According to the procedure o f 31, starting with l-amino-ethanephosphonous acid 9 (1.52
g,

13.9

mmol)

and

(n-Bu)4NOH

(8.58

g,

13.2

mmol)

to

yield

l-am ino-

ethanephosphonous acid, tetrabutyl ammonium salt 5.84 g (100%). 'H NMR (250 MHz,
CDC13) 5 0.99 (m, 12H, CH 3 (/i-Bu)4), 1.19 (2d, 7=6.95, 3H, C H 3), 1.45 (m, 8 H, C H 2 (nBu)4). 1.63 (m, 8 H, CH 2 (/i-Bu)4), 2.59 (m, IH, CHCH3), 2.29 (m, 8 H, C H 2 (n-Bu)4), 6.80
(d, 7=467.5, IH, P-H), 3lP (101 MHz, CDC13) 8 30.1.

Z-Phe-VaPF(PHO)-OH (33):
Benzyloxycarbonyl-phenylalanine (2.1 g, 7 mmol) and triethylamine (0.96 mL, 7 mmol)
were dissolved in dry toluene (5 ml). The solution was cooled to - 5 °C (ice bath with
NaCl) and treated with trimethylacetyl chloride (pivaloyl chloride, 0.86 ml, 7 mmol).
The mixture was stirred at -5 °C for 2 h, and then at room temperature for 1.5 h.
Phosphinate salt 3 (4.08 g, 10.5 mmol) in DMF (10 mL) was added to the solution and
the mixture was stirred for 24 h. Solvent was removed and the residue was dissolved in
EtOAc (20 mL) and 0.5 N HCI (20 mL). The organic layer was dried under reduced
pressure to give white solid. Yield: 2.66 g (91%). ’H NM R (200 MHz, DMSO-rfe)

8

0.95 (m, 6 H, 2CH3), 2.06 (m, IH , CH(CH3)2), 2.86 (m, 2H, C H 2 Ph), 3.77 (t, 7= 6,IH,
CHCO) 4.41 (t, 7=6, IH , CHPO), 4.95 (s, 2H, C H 2 Ph), 6.73 (d, 7=528, IH, P-H), 7.27
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(m, 10H, 2Ph), 7.54 (d, 7=8, IH , NH), 8.38 (d, 7=10, IH, NH); 3lP (101 MHz, DMSOd6) 8 27.19,27.41; FAB-M S (NBA) m /e 419.3 (M+H)+.

Z-AIa-Ala^(PHO)-OH (34):
According to the procedure o f 33, staring with Z-Ala-OH (1.79 g.

8

mmol) and 1-amino-

2-methylpropanephosphonous acid, tetrabutylammonium salt (3.92 g, 9.5 mmol) to yield
Z-Ala-AlaxF [(P H 0 )0 ]-0 H (2.3 g, 97 %). lH NMR (250 MHz, CDC13) 8 1.25-1.47 (m,
6

H, 2CH3), 3.25 (m, IH, CH CH 3), 3.78 (m, IH, CHCH3), 5.11 (s, 2H, CH 2 Ph), 6.78 (d,

7=558, IH , P-H), 7.32 (m, 5H, Ph); 3IP (101 MHz, CDC13) 8 32.7, 33.2; FAB-MS (NBA)
m /e 315.4(M+H)+.
Z -Phe-A la'F(PH O )-O H (35):
According to the procedure o f 33, staring with Z-Phe-OH (1.50 g. 5 mmol) and l-amino2-methylpropanephosphonous acid, tetrabutylammonium salt (2.15 g, 5 mL) to yield ZPhe-Ala4/[(PHO)0]-OH (1.29 g,

6 6

%). lH NMR (250 MHz, CD 3 OD)

8

1.24(m, 3H,

C H 3), 2.99(m. 2H, CHCH 2 Ph), 4.04 (m, IH, CHBn), 4.39 (m, IH, CHCH3), 5.06 (s, 2H,
C H 2 Ph), 6.77 (d, 7=557, IH, P-H), 7.23 (m, 10H, Ph); 31P (101 MHz, CD 3 OD)

8

30.6;

FAB-MS (NBA) m /e 389.7 ((M-H) ).
Z-Phe-VaPF(PHO)-OAUyl (36):
Z-Phe-VaI*F(PHO)-OH 31 (0.42g, 1 mmol) and allyl ester (0.075 mL, 1.1 mmol) were
dissolved in CH 2 Cl2

(8

mL). DM AP (12 mg, 0.1 mmol) was added to the solution, then

DCC (0.22 g, 1.1 mmol) was added. The mixture was stirred for 5 h, and diluted with
EtOAc (60 mL), filtered and washed successively with 5% K H S0 4 (30 mL), saturated
N aH C 0 3 (30 mL) and NaCl solutions (30 mL), dried over Na2 S 0 4 and evaporated the
solvent to give phosphonous monoester. Yield: 0.39 g (82%).

'H NMR (200 MHz,
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CD 3 OD)

8

0.78-1.11 (2d, 6 H, 2CH3), 2.12 (m, IH, CH(CH3)2), 3.08 (m, 2H, C H 2 Ph),

4.17 (m, IH, CHPO), 4.48 (m, 3H, CH=CH2+ CHBn), 5.07 (s, 2 H, C H 2(Z)), 5.35 (m, 2H,
NH + C H 2 CH=CH2), 5.86 (m, IH, CH=CH2) 7.00 ( d, IH, P-H, 7=551), 7.26 (m, 10H,
2Ph); 3lP (101 MHz, CD 3 OD) 5 3 2.3,32.6,32.9; FAB-MS (NBA) m/e 495.3 (M + H )\

General experimental conditions for solution phase synthesis of phosphonopeptides
At room temperature, a solution of Ph 3 PCl 2 (95% purity, Aldrich, 1.2 eq.) in CH 2 C12 was
added dropwise to a solution of dipeptide phosphonous acid ester with stirring.
Concentrations were chosen such that the reaction mixture contained 0.1 M dipeptide
phosphonous acid ester. 30 min. later, TEA (3 eq.) was injected into the reaction solution
to scavenge HCI. Then the solution was treated with hydroxyl acid ester (2 eq.) for 1.5 h,
followed by addition of t-BuOOH o r Sg (10 eq.) for at least 1.5 h. The solution was
washed with saturated aqueous N aH C 0 3 and dried over Na 2 S 0 4.

3IP and FAB-MS

identified the compounds.

Synthesis of Z-Phe-VaPF[(P0 2Allyl)0]-Phe-OAllyl (39):
At room temperature, a solution of Ph 3 PCl 2 (95% purity, Aldrich, 1.5 eq.) and TEA (3
eq.) in CH 2 C12 was added dropwise to a solution o f Z-protected dipeptide phosphonite
ZFVp-0A llyl (0.19g, 0.4 mmol) with stirring for 45 min. Then the solution was treated
with hydroxyl acid allyl ester (0.12g, 0.6 mmol) for 1.5 h (3lP NMR 136), followed by
addition o f t-BuOOH (0.12 mL, 4 mmol) for at least 1.5 h. The solution was washed
with saturated aqueous N aH C 0 3 and dried over Na 2 S 0 4 to give 0.487g.

After flash

Column chromatograph (CHCl3-EtOAc 5:1), desired product was obtained (O.lOlg,
38%). 3lP (101 MHz, CDC13) 8 23.8,24.2; FAB-MS m /e 663.2 (M+H)+.
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Preparation and test of resin-bound PhsPCh (4D :64
The resin-bound PhjP (0.5 g, 1.5 mmol) was swelled in DCM (2 mL), and a solution o f
triphosgene (0.148 g, 0.5 mmol) in DCM (I mL) was added whilst cooling to maintain
the temperature at 20 °C. After the addition the reaction was stirred until gas evolution.
Solid-phase 31P NMR showed a broad Ph 3 PCl 2 signal 58.3 ppm. A solution of Fmoc
amino phosphonite (0.154 g, 0.3 mmol) and triethylamine (0.068 mL, 0.5 mmol) in
dichloromethane was injected into the flask containing resin-bound Ph 3 PCl2. The 3IP
NMR signal of the activating species was detected 5 192 ppm, as well as other by
products

8

218, 233, 234 ppm. However, after coupling with hydroxyl acid ester and

followed by oxidation step, the product was detected (25 ppm) with other by-product 34
ppm.

Preparation and test of PhjPFj (42):65
Triphenylphosphine (43 mg, 0.16 mmol), potassium hydrogen fluoride (65 mg, 0.83
mmol), and dry DM F (2 mL) were placed in an NMR tube under argon. The solution
was shaken to dissolve the triphenylphosphine, cooled to 0 °C, and following the addition
of diisopropylazodicarboxylate (33 pL, 0.16 mmol), placed in a sonic bath for 2 hrs. 3IP
NMR showed clean conversion to diflorotriphenylphosphorane
was a small singlet at

8

8

55.8 ppm. Also present

25.1, due to triphenylphosphine oxide. A solution o f Fmoc

amino phosphonite (30 mg, 0.06 mmol) and triethylamine (0.02 mL, 0.1 mmol) in
dichloromethane (1 mL) was injected into the NMR tube. But no the 3lP NM R signal of
the activating species was detected.
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Synthesis of Z-Phe-Val'F[(P02')0]-Phe-OAUyl (50) by general procedure:
At room temperature, a solution of Ph 3 PCl2 (1.1 eq.) in CH 2 CI2 was added to a solution of
Z-protected dipeptide phosphonite 36 (172 mg, 0.38 mmol). After 30 minutes, 3IP NMR
indicated peaks o f activated P(III) compound (5=182, 184). This solution was treated
with TEA (0.15 mL, 1 mmol) for 60 minutes (8=179, 180), followed by adding Lphenyllactic acid allyl ester 28b (116 mg, 0.56 mmol). 3lP NMRs showed peaks (8173,
174). r-Butylperoxide (0.5 mL, 3.8 mmol) was used for oxidation step for 2 h. 31P (101
MHz, CDCI3 )

8

25.4, 25.7; FAB-MS m/e 621.2 (M -H )\

Synthesis of Z-Phe-VaPF[(POS')0]-Phe-OAIlyl (51) by general procedure:
At room temperature, a solution o f Ph 3 PCl 2 (1.1 eq.) in CH 2 CI2 was added to a solution of
Z-protected dipeptide phosphonite 36 (260 mg, 0.57 mmol). After 30 minutes, 3,P NMR
indicated peaks of activated P(IH) compound (8=182, 184). This solution was treated
with TAE (0.3 mL, 1.6 mmol) for 60 minutes (5=179, 180), followed by adding Lphenyllactic acid allyl ester (175 mg, 0.85 mmol). 3IP NMRs showed peaks (8 = 173,
174). Sulfurization was completed through treated with sulfur (0.18 g, 5.7 mmol) for 4 h.
3IP NMR indicated the peaks of product clearly (8=76-78,94,95); FAB-MS m /e 637.2
(M -H )\

Reaction mechanism studies:
A Z-protected aminophosphonous acid neopentyl ester 19 was treated with 1.5 eq.
Ph 3 PCl 2 in the absence o f base for 30 minutes. The solution then was filtered through
DIEA resins to remove HCI. The nitrate was then injected to GC-MS to analyses. GCMS: m /z 5 5 ,5 7 ,9 1 (M + l, 78%).
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Non-nucleophilic base experiment:
2,6-d/-f-Butyl-4-methyl-pyridine was used instead of TEA or DIEA, it was found that
hydroxyl acid ester was able to couple to the phosphinate acid ester (Scheme 3.2.2.8). 3lP
(101 MHz, CDCI3 ) 8 76.4,78.0; FAB-MS m /e 637.6 (M -H)\

DIEA-PS base experiment:
In an argon glovebox, Fmoc-aminophosphonous acid benzyl ester (90 mg, 0.2 mmol) was
activated by 1.5 equivalents of PhsPCb. The solution was transferred to a container
holding DIEA-PS (272 mg, 5 equiv.). After 2 h, the resins were filtered off. Both
solution and resin were taken out to run 3lP NMR. In solid phase, no desired peak was
detected; in solution phase, only activation peaks were found: 31P (101 MHz, CDCI3 ) 8
192.
In next experiment, followed by base attachment step, hydroxyl acid methyl ester was
injected in for 2 h, then Sg. 3,P NMR studies indicated that after injection of activated
aminophosphonous acid ester to resin-bound DIEA-PS, the mixture o f the resins and
solution displayed the peak o f activation (8=192) and the peak o f Ph3PO (8=27.5); the
resins themselves just had Ph 3 PO signal. When sulfurization step finished, the dipeptide
product peaks were found in solution; 31P (101 MHz, CDC13) 8 87, 89; FAB-MS m/e
552.5 (M -H)\

Z-Phe-Val'P(PHO)-OBn (52):
Z-Phe-ValvP(PHO)-OH 31 (0.26g, 0.6 mmol) and benzylester (0.071 mL, 0.66 mmol)
were dissolved in CH^CL (5 mL). DMAP

(8

mg, 0.06 mmol) was added to the solution,

then DCC (0.16 g, 0.66 mmol) was added. The mixture was stirred for 5 h, and diluted
with EtOAc (30 mL), filtered and washed successively with 5% KHSO 4 (20 mL),
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saturated NaHCC>3 (20 mL) and NaCI solutions (20 mL), dried over Na2 SC>4 and
evaporated the solvent to give phosphonous monoester. Yield: 0.29 g (90%). ’H NMR
(250 MHz, CD 3 OD) 5 0.76-1.11 (2d, 6 H, 2CH3), 2.15 (m, IH, CH(CH3)2), 3.06 (m, 2H,
C H 2 Ph), 4.15 (m, IH, CHPO), 4.45 (m, IH, CHBn), 5.07 (m, 4H, C H 2(Bn) + CH 2(Z)), 5.25
(d, IH , NH), 7.00 ( d, IH, P-H, J=551), 7.26 (m, 15H, 3Ph); 31P (101 MHz, CD 3 OD)

8

33.8,34.0, 34.3.
PI1 3 PCI 2 titration
At room temperature, a solution o f Ph 3 PCl 2 (0.2-0.3 mL, 0.5-0.75 equiv.) in CH 2 C12 was
added dropwise to a solution of dipeptide phosphonous acid ester 52 (76 mg, 0.15 mmol)
with stirring. Concentrations were chosen such that the reaction mixture contained 0.1 M
dipeptide phosphonous acid ester.

3lP NMR (38 ppm) showed no activation signal.

DIEA (0.078 mL, 3 eq.) was added into the reaction solution to scavenge HCI. Then the
solution was treated with hydroxy acid ester 28b (93 mg, 3 equiv.) for 1.5 h, followed by
addition of Sg (32 mg, 10 equiv.) for at least 1.5 h. The solution was washed with
saturated aqueous N aH C 0 3 and dried over Na 2 S 0 4 . 31P (101 MHz, CD 3 OD)
FAB-MS m /e 539.2 (M -H )\
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8

73, 74;

CHAPTER 4. SYNTHESES OF PHOSPHONATE AND
THIOPHOSPHONATE PEPTIDE ANALOGS BY
ESTERIFICATION-OXIDATION STRATEGY
Although

the

P(HI)

chemistry

we

developed

to

synthesize

phosphono-

and

thiophosphonopeptide (Chapter 3) has the advantage such as less reaction time needed,
we experienced many side reactions. In this chapter, an alternative strategy for preparing
phosphonate and thiophosphonate peptide analogs is illustrated. After the phosphonous
acid dipeptide analogs are made, esterification is completed in the presence o f
DCC/DMAP or just EDC. The reduced phosphorus [P(III)] tripeptide derivatives are

51,71

50,70

72, 73

74, 75
Ph

Ph

76, 77

78, 79

50, 51, 72, 74, 76,78: R = Allyl; 70, 71,73, 75, 77, 79: R = CH3

Fig. 4 Phosphonate and thiophosphonate peptide analogs.
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oxidized by sodium periodate to afford the P(V) peptide analogs; or sulfurized by Ss in
pyridine/carbondisulfide solution to give thiophosphonopeptide products (Fig. 4.1). This
approach avoids some o f the side reactions we experienced when using one pot strategy
and the reaction condition is relative milder. The methyl ester protecting groups are
cleaved by lithium n-mecaptide in hexamethylphosphoramide; and the allyl ester
protecting groups are deblocked by reactions catalyzed with Pd(PPh 3 ) 4 Sep-Pak or HPLC
column purification gives the target molecules.

4.1 Synthesis of Phosphonotripeptide Analogs
Karanewsky and Badia (1986) described a strategy 5 1 to make phosphonites by
condensing amino phosphonous acids with alcohol.

Following this procedure, we

coupled the Z-protected phosphonous acid dipeptide analogs directly to C-terminal a hydroxy acid ester by carbodiimide mediated dehydration to give H-phosphonite
tripeptide analogs 80-85 in 80-90% yields (Scheme 4.1.1).

1 .Hydroxyl acid e s te r
2.DMAP
3.D CC

80: R 1=Bn, R 2 =/Pr, R=M e; 81: R ^ B n , R2 =/Pr, R=Allyl;
82: R 1=Bn, R 2 =Me, R=M e; 83: R ^ B n , R 2=Me, R=Allyl;
84: R 1=M e, R 2 =Me, R=M e; 85: R 1=Me, R 2=Me, X=Allyl.

Scheme 4.1.1 Synthesis o f H-phosphonites tripeptide analogs.
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However, using the purification procedure51 described by Karanewsky and Badia,
we were not able to get pure products since aqueous extraction couldn’t remove all DCU
by-products.
phosphonous

Applying a modification of the carbodiimide-mediated approach, the
acids

and

hydroxy

acid

esters

were

coupled

with

l-[3-

(dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) (Fig. 4.2) in a yield of
70-90%. We found that the catalyst DMAP was unnecessary when using EDC as the
activator and the EDC was more easily removed from the products by simple aqueous
extraction. Use o f the water-soluble carbodiimide proved to be important in facilitating
the reaction workup, since silica gel chromatography, to which the phosphinate esters
were not stable, could be avoided.
H3C ,
N -C H 2 CH 2 CH 2 -N = C = N -C H 2 CH 3 .HCI
h 3c

Fig. 4.1 l-[3-(dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC).

Following the literature procedure , 51 oxidation o f H-phosphintes 80-85 with
sodium periodate produced the phosphonate peptide analogs 50, 70, 72, 73, 76 and 77
(Scheme 4.1.2).

Iioxane

80-85

50, 70, 72, 73, 76, 77

Scheme 4.1.2 Oxidation of H-phosphinates.
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In oligonucleotide chemistry, the synthesis o f an oligodeoxynucleotide containing
phosphorothioate diester can be accomplished by sufurization o f phosphite intermediates
with elemental sulfur in carbon disulfide/pyridine . 6 8 However, when H-phosphonates
intermediates are used, sulfur requires the presence of more basic tertiary amine like
TEA . 6 9

In analog to this, direct sulfurization of H-phosphinates

by S8 in

pyridine/carbondisulfide required the presence of TEA to provide thiophosphonates 51,

71, 74, 75, 78, 79 in 40-80% yields (Scheme 4.1.3).
chromatography resulted in loss of products.

Purification by flash

It might be caused by hydrolysis of

products on silica gel or low solubility o f the charged products in the organic mobile
phase . 16 The desired compounds were confirmed by FAB-MS, *H and 3IP NMR. The
compounds were hard to be isolated from DCC and the reaction by-product DCU, the
purity were 39%-44%of according to HPLC analysis.

52

H

H

£

►

80-85

=2

H

1
OH

£
=

5 1 ,7 1 ,7 4 ,7 5 ,7 8 ,7 9

Scheme 4.1.3 Sulfurization of H-phosphinates.

4.2 Esters Deprotection
4.2.1 Deprotection of Methyl Esters
Lithium n-propyl mercaptide in hexamethylphosphoramide (HMPA) is an especially
effective reagent for the cleavage of methyl ester under mild conditions. The reaction
proceeds readily at room temperature by an Sn2 mechanism . 7 0 The reagent was prepared
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by adding freshly n-propyl mercaptan to a suspension o f ground lithium hydride in pre
purged HMPA under argon, stirred for 1 h, then followed by filtration without contact
with air. The reagent was stored at 0 °C without removal o f the excess mercaptan . 71
The

tripeptide

analogs

Z-Phe-Val\j/[P( 0 2 ') 0 ]Phe- 0 Me

70

and

Z-Phe-

V al\j/[P(0S)0]Phe-0H 71 were treated with n-propyl mercaptide (0.46 M) in HMPA for
2.5

h. The mixture was diluted with water, and washed six tim es with CHCI3 to remove

HMPA. The aqueous phase was lyophilized to yield a white powder. The tripeptide
analog sample was dissolved in 50 mM TEAA, loaded to a Cis Sep-Pak cartridge, which
was prewashed with Water, MeOH, and 50 mM TEAA. The sample was eluted with 0%
to 80% CH 3 CN in 50 mM TEAA.

The desired tripeptide analogs l a and lb were

obtained in the form o f triethylammonium salts after Sep-Pak Column purification.
However, employing this deprotection strategy to other methyl esters 73, 75, 77 and 79,
either led to no cleavage or decomposition of the starting materials, which indicated these
phosphonopeptides were not stable as 70 and 71 to the cleavage reagent.

> -N H
°

n
Bn

O

y - NH

y

0

y

?n
1,CH 3 CH 2 CH2 S U / 0
V -f
r *
Bn
HN— (
1
HMPA
Bn'
HN— (
T
^
J p x- ° c o r
0 * P \- °
c o 2 c h 3 -------------------------------X—.
2. S e p -P a k colum n
0
x
u
purification
Q

70: X = O ; 71: X = S

ia : X = 0 ; 1b:X = S

Schem e 4.2.1 Deprotection o f methyl esters.
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4.2.2 Deallylation o f Allyl Esters
Allyl and allyloxyxarbonyl groups are used for the protection of amino acids72,73 and as
linker for solid-phase peptide synthesis.74,73 The use of such anchoring groups for the
synthesis of protected peptide segments is attractive because, in principle, they are
compatible with both the Boc- and Fmoc- peptide synthesis strategies. Moreover for the
Fmoc strategy the allylic anchor provides a three-demensional orthogonal protecting
scheme. The protecting groups may be selectively cleaved using various nucleophile
reagents under palladium catalysis.76,77 The mechanism of “allyl” group deprotection
involves the formation o f an allyl-palladium complex which further reacts which the
nucleophile to give X ' and the regenerated catalyst (Scheme 4.2.1).72 We felt that under
these

mild

conditions,

that

final

ally

ester cleavage

would

occur

and

the

phosphonopeptides would be stable.
Nu0

_

^

©

Pd° catalyst

Schem e 4.2.2.1 The mechanism of allyl group deprotection.

The catalyst tetrakis(triphenylphosphine) palladium (0) was prepared.78

The

mixture o f palladium dichloride and triphenylphosphine in dimethyl sulfoxide (DMSO)
was heated to 140 °C. Hydrazine hydrate was then rapidly added. After crystallization,
yellow crystalline product was obtained (91% yield).
1 . P d C I 2/ D M S O
Heat
2. NH2NH2H20
P P h 3 ------------------------------

P d ( P P h 3)4

Schem e 4.2.2.2 Preparation o f tetrakis(triphenylphosphine) palladium (0).
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Phosphonopeptide allyl ester was dissolved in dichloromethane or DMF. To the
flask was then added 2 equivalents morpholine or PhSiHj, followed'by Pd(PPh 3 )4 . The
solution was stirred at room temperature for 60 minutes. Polystyrene supported PPh 3
resins were added to scavenge Pd and stirred for 60 min, then filtered off by suction
filtration and washed with DCM. All solvents were evaporated by reduced pressure, and
the products were dried under vacuum.

Purification was performed with Sep-Pak or

reverse phase HPLC to get oily products.

0.
^~N H
O
0
>H :
Ra
Ri HN—(

n ^ P -0
°
x
©

5 0 ,5 1 ,7 2 ,7 6 ,7 8

Bn

X

1. morpholine
or PhSiH3
2. P d(P P h3)4
3. P P h 3-Resin

C 02Allyl------------ ►
4. Sep-Pak
purification

Q
^ -N H
O
O
> -(
R2
HN— <

n* P r°
° \
. ..©

Bn

X

<=>

CG^

. ...
1a, 1b,1 c, 1e,1 f

Scheme 4.2.2.3 Deprotection of allyl esters.

74

Fig. 4.2.1 HPLC o f Profile Z-Phe-Ala'P[(POS )0]-Phe-OAllyl 74. linear gradient over 60
min o f 65% solution A (0.25M ammonium acetate in HiO) and 35% solution B
(0.05M ammonium acetate in CH 3 CN-H 2 O 4:1); purity 39%; tR= 15.9 min.
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50

1a

(1)

(2)

Fig. 4.2.2 HPLC o f profiles of 50 and la. (1) Z-Phe-Val4 /[(P 0 2 ’)0 ]-Phe- 0 AIlyl 50;
linear gradient over 60 min o f 65% solution A (0.25M ammonium acetate in
H 2 0 ) and 35% solution B (0.05M ammonium acetate in CH 3 CN-H 2 O 4:1);
purity 44%; tR= 15.1,15.9 min. (2) Z-Phe-Val 4 /[(P 0 2 ")0 ]-Phe- 0 H la ;
linear gradient over 60 min o f 65% solution A (0.25M ammonium acetate in
H 2 0 ) and 35% solution B (0.05M ammonium acetate in CH 3 CN-H 2 O 4:1);
purity 76%; tR= 10,10.5 min
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51
-S
it*!

(1)
1b

(2)

Fig. 4.2.3 HPLC o f profiles o f 51 and lb . (1) Z-Phe-VallF[(P0S‘)0]-Phe-0A llyl 51;
linear gradient over 60 min o f 65% solution A (0.25M ammonium acetate in
H 2 O) and 35% solution B (0.05M ammonium acetate in CH 3 CN-H20 4:1);
purity 42%; tR= 28.8min. (2) Z-Phe-V al'P[(P0S')0]-Phe-0H lb;linear
gradient over 60 min o f 65% solution A (0.25M ammonium acetate inH2 0 ) and
35% solution B (0.05M ammonium acetate in CH 3 CN-H20 4:1); purity 8 8 %;
tR = 9 .7 ,10.5 min
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(1)

so

(2)
Fig. 4.2.4 HPLC of profiles o f 76 and le . (1) Z-Ala-AlavP [(P 0 2 )0]-Phe-0A llyl
76; linear gradient over 60 min of 65% solution A (0.25M ammonium
acetate inH 2 0 ) and 35% solution B (0.05M ammonium acetate in
CH 3 CN-H20 4:1); purity 43%; tR= 17.2 min. (2) Z-A la-A laTK PO ^O ]Phe-OH le ; linear gradient over 60 min o f 95% solution A (0.1M TEAA
in H 2 0 ) and 5% solution B (0.02M TEAA in CH 3 CN-H 2 0 4:1), flow rate
1 mL/min on a C-18 column; purity 6 %;tR= 24.6 min.
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(1)

4<H

»-

(2)

Fig. 4.2.5 HPLC o f profiles o f 78 and If. (1) Z-Ala-Ala'F[(P0S )0]-Phe-0A Ilyl 78;
linear gradient over 60 min of 65% solution A (0.25M ammonium acetate in
H 2 O) and 35% solution B (0.05M ammonium acetate in CH 3 CN-H20 4:1),
purity 65%; tR= 15.8 min. (2) Z-Ala-Ala4'[(P0S*)0]-Phe-0H If; linear
gradient over 60 min o f 95% solution A (0.1M TEAA in H 2 0 ) and 5%
solution B (0.02M TEAA in CH 3 CN-H20 4:1), flow rate 1 mL/min on a C18 column; purity 10%;tR= 24.1 min.
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Fig. 4.2.6 HPLC of profiles of 72 and lc . (1) Z-Phe-AlavP [(P 0 2 )0]-P he-0A llyl 72;
linear gradient over 60 min o f 95% solution A (0.1M TEAA in H 2 0 ) and
5% solution B (0.02M TEAA in CH 3 CN-H 2 0 4:1), flow rate 1 mL/min on a
C-18 column; purity 38%;tR= 23.5, 24.6 min. (2) Z-Phe-A la'P[(P0 2 ')0 ]Phe-OH lc . linear gradient over 60 min o f 95% solution A (0.1M TEAA in
H 2 0 ) and 5% solution B (0.02M TEAA in CH 3 CN-H 2 0 4:1), flow rate 1
mL/min on a C-18 column; purity 62%;tR = 28.7 min.
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We could not obtain some target molecules. In some cases, after deprotection o f allyl
ester, only the starting reagents, peptide esters, were found. It’s probably because the
anion moiety, bonded with phosphorus atom, attacks the palladium complex to deactivate
the catalyst.

In some cases, phosphonopeptides were obtained after deblocking the

thiophosphonopeptide esters. We assumed that S' reacted with palladium catalyst to form
a thioallyl ester, which during the aqueous workup process was hydrolyzed to displace
the sulfur moiety. (Scheme 4.2.2.4)

Scheme 4.2.2.4 Possible mechanism o f Desulfurization of thiophosphonopeptide to
phosphonopeptide.

4.3 Enzyme Assays
The effectiveness o f a molecule as a reversible enzyme inhibitor is gauged quantitatively,
usually by the inhibition constant K\ but also by the rate constant for dissociate,

E*l

E + 1

KS = W A b n = [ E ] [ l ] / [ E * l ]

* o ff

The approaches to determination o f very low inhibition constants rely on the
independent determination of the association and the dissociation constants, koa and k0ff,
respectively. If inhibition is reversible, the ratio o f kQff/kon can be taken as K\. While £0ff
is most readily determ ined by measuring the rate o f inactivation of the enzyme as a
function o f inhibitor concentration, methods for determining kM vary. Determinations o f
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K\ s of CPA inhibitors la and lb required the used o f a coupled assay to determine itoff
because of the extremely slow dissociation o f the inhibitors from CPA (Scheme 4.3 ) . 2 2

CPA*Inhibitor - — — -

CPAfree +

Inhibitor

free CPA

HO"

°e
L actate
dehydrogense

NAD

NADH, H
Tyrosine
am inotransferase

.0
0@

aKg

Glu

Scheme 4.3 Kinetic enzyme assay to measure dissociate o f inhibitors from
carboxypeptidase (CPA): rate of NADH production is measured by
fluorescence (Aex = 340 nm; Aem = 450 nra) and is proportional to

[CPAfree]*
Our results with the known ZFVp(0 )F inhibitor la agree with the Bartlett’s
value: 18

=

105 M ^s ' 1 (literature 2.1 x 105 M ' s 1); k0a = 4.5 x 10' 9 M 's ’ 1 (literature

2.9 x 10' 9 M'*s'1); and the inhibition constant K\ - 1.1 x 10' 14 M (literature 1.4 x 10' 14 M).
We have also analyzed the thiophosphonate inhibitor lb and shown for the first time that
thiophosphonates are also extremely potent inhibitors of the zinc protease CPA:
ko„ = 3 x

105 M

V ; ito ff

= 3.9 x

1 0 '9 M

V 1;

and Kt = 1.3 x

10

*,5 M .
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4.4 Experim ental M aterial
Analytical HPLC were performed on SUPELCOSIL LC 18S (0.46 x 25 cm), module on
PERKIN ELMER 200 series autosampler and pump equipped with 785A UV/VIS
detector. The preparative HPLC were performed on Waters PrepLC 25mm (2.5 x 10
cm), module on a Waters Millipore 600 E system equipped with a variable wavelength
detector and an autoinjector.
Z-Phe-VaI*F[(PHO)0]-Phe-OMe (80):
Z-Phe-Val4/[(PHO)]-OH (0.63 g, 1.5 mmol) 34 and L-3-phenyllactic acid, methyl ester
(0.3 g, 1.65 mmol) were dissolved in CH 2 CI 2 (10 mL). DMAP (18 mg, 0.15 mmol) was
added to the solution, then DCC (0.32 g, 1.58 mmol) was added. The mixture was stirred
for 5 h, and diluted with EtOAc (100 mL), filtered and washed successively with 5%
KHSO4 (60 mL), saturated NaHC 0 3 (60 mL), and NaCl solutions (60 mL), dried over
Na2 S0

4

and evaporated the solvent to give phosphonous monoester. Yield: 0.85 g (97%).

*H NMR (250 MHz, CDC13) 8 0.72-0.95 (2d, 6 H, 2CH3), 1.95 (m, 1 H, CH(CH 3 )2 ), 3.14
(m, 4H, 2CH 2 Ph), 3.78 (m. 4H, OCHCO+CH3), 4.11 (m, 1H, CHCO), 4.48 (m, 1H,
CHPO), 5.06 (m, 2H, CH2(Z)), 6.29 (d, 7=7, 1 H, NH),

6 .6 6

(d, 7=565, 1 H, P-H), 7.26 (m,

15H, 3Ph); 3,P (101 MHz, CDC13) 5 31.8, 32.9, 34.6; FAB-MS m/e 581.0 (M+H)+.
Z-Phe-V aPF[(PH 0)01-Phe-0A llyl (81):
Z-Phe-Val'P[(PHO)]-OH 34 (0.84g, 2 mmol) and L-3-Phenyllactic acid allyl ester (0.46
g, 2.2 mmol) were dissolved in CH 2 CI2 (15 mL). DMAP (24 mg, 0.2 mmol) was added
to the solution, then DCC (0.43 g, 2.1 mmol) was added. The mixture was stirred for 5 h,
and diluted with EtOAc (120 mL), filtered and washed successively with 5% KHSO 4 (60
mL), saturated N aH C 0 3 (60 mL) and NaCl solutions (60 mL), dried over Na 2 S 0 4 and
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evaporated the solvent to give phosphonous monoester. Yield: 1.08 g ( 8 6 %). *H NMR
(250 MHz, CD 3 OD)

8

0.78-1.11 (2d, 6 H, 2C H 3), 2.12 (m, 1H, CH(CH3)2), 2.26 (m, IH,

CHCO) 3.08 (m, 4H, 2CH 2 Ph), 4.05 (m, 1H, CH PO ), 4.50 (m, 3H, CH=CH2+ OCHCO),
5.18 (m, 2H, C H 2(Z)), 5.30 (m, 2H, C H 2 CH=CH2), 5.81 (m, IH, CH=CH2) 7.25 (m, 15H,
3Ph); 3IP (101 M Hz, CD 3 OD)

8

32.3, 32.6, 32.9.

Z-A la*A la'F[(PH O )0]-Phe-O M e (84).
A 25-mL round bottom flask was charged with a solution of Z-Ala-AlaH'tfPHOjOJ-OH
36 (157 mg, 0.5 mmol) and hydroxyl acid methyl ester (99 mg, 0.55 mmol) in 5 mL
CH 2 C12.

EDC (lOOmg, 1.05 mmol) was added.

temperature for 20 h.
saturated KH 2 P 0

4

The mixture was stirred at room

The solution was diluted with EtOAc (60 mL), washed with

(60 mL), saturated N aH C 0 3 (60 mL) and brine (60 mL), dried over

Na2 S0 4 , and evaporated to give peptide(PIH) analog. Yield: 182 mg, (77% yield). lH
NMR (250 M Hz, CDC13)

8

1.12-1.52(m, 6 H, 2C H 3), 3.69 (m, 3H, CHCO+CH 2 Ph), 3.72

(d, IH, OCHCO), 3.78 (s, 3H, O CH 3), 4.46 (m, IH, CHPO), 5.10 (m, 2H, CH 2(Z)), 7.20
(d, 7=587, IH, P-H), 7.28 (m, 10H, 2Ph); 31P (101 M Hz, CDC13) 5 33.0, 33.8, 35.6, 36.0;
FAB-MS m/e A l l . 5 (M +H)+.
Z-Ala-Ala'F[(PH O )0]*Phe-OA Ilyl ( 8 6 ):
According to procedure of 84, staring with Z-Ala-AIa'F[(PHO)]-OH 36 (0.4 g, 1.3 mmol)
and L-3-Phenyllactic acid allyl ester (0.29 g, 1.4 mmol) to yield Z-Ala-Ala4/[(PH O )0]Phe-0Allyl (583 mg, 91%). *H NMR (250 M Hz, CD 3 OD)

8

0.94-1.30 (m, 6 H, 2CH 3),

3.10 (m, 4H, 2C H 2 Ph), 3.29 (m, IH , CHCO), 4.26 (m, IH, CHPO), 4.47 (t, IH,
OCHCO), 4.65 (m, 2H, CH=CH2), 5.10 (m, 2H, C H 2(Z)), 5.36 (m, 2H, CH 2 CH=CH2),
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5.95 (m, IH, CH=CH2), 6.98 (d, 7=560, IH, P-H), 7.25 (m, 10H, 2Ph); 3lP (101 MHz,
CD 3 OD)

8

32.7,34.6, 34.8; FAB-MS (NBA): m/e 503.5 (M+H)+.

Z -P h e-A la4 '[(P H 0 )0 ]-P h e-0 M e (82):
According to procedure of 84, staring with Z-Phe-Ala'P[(PHO)]-OH 35 (0.59 g, 1.5
mmol) and L-3-Phenyllactic acid methyl ester (0.30 g, 1.7 mmol) to yield Z-PheAla'F[(PHO)0]-Phe-OM e 82 (0.73 g, 93%). ‘H NMR (250 MHz, CDC13) 5 1.03-1.31
(m, 3H, C H 3), 3.10 (m, 4H, 2CH 2 Ph), 3.22 (t, IH, (OCH(Bz)CO), 3,72 (s, 3H, CH3),
4.19 (m, IH, CHCO), 4.37 (m, IH, CHPO), 5.08 (s, 2H, CH2(Z)),

6 .8 8

(d, 7=565, IH, P-

H), 7.26 (m, 10H, 2Ph); 3IP (101 MHz, CDC13) 5 32.6, 34.9, 35.2; FAB-MS m/e 553.7
(M+H)+.
Z -P he-A la'P [(P H 0)0]-P he-0A llyl (83):
According to procedure of 84 with EDC instead o f DCC/DMAP, staring with Z-PheAlaH/[(PHO)]-OH 35 (0.39 g, 0.8 mmol) and L-3-Phenyllactic acid allyl ester (0.18 g,
0.88 mmol) to yield Z-Phe-AlavF[(PHO)0]-Phe-OAllyl 83 (393 mg, 85 %). ‘H NMR
(200 MHz, CDCI3 ) 5 0.94-1.30 (m, 3H, CH 3), 3.10 (m, 4H, 2CH 2 Ph), 4.17 (m, IH.
CHCO), 4.27 (m, IH, CHPO), 4.65 (m, 3H, OCHCO+CH=CH2), 5.07 (m, 2H, C H 2 (z)),
5.37 (m, 2H, CH 2 CH=CH2), 5.88 (m, IH, CH=CH2), 6.98 (d, 7=560, IH, P-H), 7.25 (m,
15H, 3Ph); 3,P (101 MHz, CD 3 OD) 5 33,35, 35.4,35.7; FAB-MS (NBA): ni/e (M + H f.
Z-Phe-ValvP [(P 0 2 )0]-P he-O M e (70):
Z-Phe-Val'P[(PHO)]-Phe-OMe 80 (0.29 g, 0.5 mmol) was taken up in dioxane (1 mL)
and treated with N aI0 4 (0.13 g, 0.6 mmol) in water (1 mL).

After stirring at room

temperature for 5 h, the mixture was filtered then partitioned between EtOAc and 2%
KHSO 4 (10 mL each). The organic phase was washed successively with water (20 mL),
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5% NaHS 0 3 (20 mL) and saturated NaCl solution (20 mL), dried over Na 2 S0 4 and
evaporated to give crude 70 (230 mg). The crude product was purified by flash column
chromatography (silica gel, MeOH-CHCb 1:9). Reverse phase analytical HPLC: linear
gradient over 45 min of 100% solution A (0.1% TFA in H 2 0 ) and 0% solution B (0.1%
TFA in CH 3 CN-H 2 O 4:1), flow rate I mL/min over 40 min on a C4 column; tR = 34.1
min. Amino acid analysis: 74.9%.
CD 3 OD)

8

Yield: 120 mg (41.4%).

‘H NMR

(250 MHz,

0.81-0.96 (2d, 6 H, 2CH3), 2.15 (m, IH, CH(CH3)2), 3.12 (m, 4H, 2CH 2 Ph),

3.59 (m, 4H, OCHCO+CH 3 ), 4.05 (m, IH, CHCO), 4.48 (m, IH, CHPO), 4.99 (m, 2H,
C H 2(Z)), 7.22 (m, 15H, 3Ph); 31P (101 MHz, CD 3 OD)

8

18.8, 18.9; FAB-MS m/e 495.7

(M+H)+.
Z-Phe-VaPF[(PO2 )O]-Phe-OAIIyl(50):
Compound Z-Phe-Val'P[(PHO)0]-Phe-0Allyl 81 (0.61 g, 1 mmol) was taken up in
dioxane (2 mL) and treated with NaI0

4

(0.26 g, 1.2 mmol) in water (2 mL). After

stirring at room temperature for 5 h, the mixture was filtered then partitioned between
EtOAc and 2% K H S04 (20 mL each). The organic phase was washed successively with
water (20 mL), 5% NaHS 0 3 (20 mL) and saturated NaCl solution (20 mL), dried over
Na 2 S0 4 and evaporated the solvent to give crude product (612 mg). The crude product
was purified by flash column chromatography (silica gel, MeOH-CHCb 1:12). Yield:
269 mg (41%). Analytical HPLC: linear gradient over 55 min o f 65% solution A (0.25M
ammonium acetate in H 2 0 ) and 35% solution B (0.05M ammonium acetate in CH 3 CNH20 4:1), flow rate 1 mL/min on a SUPELCOSIL LC 18S column; tR= 15.07, 15.86 min.
lH NMR (250 MHz, CD 3 OD) 8 0.83-0.97 (2d, 6 H, 2CH3), 2.13 (m, IH, CH(CH3)2), 2.28
(m, IH, CHCO) 3.10 (m, 4H, 2CH 2 Ph), 4.04 (m, IH, CHPO), 4.48 (m, 3H, CH=CH2+
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OCHCO), 5.18 (m, 2H, CH 2(Z)), 5.32 (m, 2H, C H 2 CH=CH2), 5.79 (m, IH, CH=CH2)
7.25 (m, 15H, 3Ph); 3lP

(101 MHz, CD 3 OD) 5 17.5; FAB-M S (NBA): m/e 622.5

(M+H)+.

Z-Ala-AIa'F[(P02 )0]-Phe-0M e (77):
According to procedure of 70, staring with Z-Ala-AlaxP[(PHO)]-Phe-OM e 76 (91 mg, 0.2
mmol) to yield Z-Ala-AlalP[(P0 2 )0]-P he-0M e 77 (74 mg, 79%). 'H NM R (250 MHz,
CDCI3 )

8

1.07-1.14(m, 6 H, 2CH3), 2.96 (m, IH, CHCO), 3.12 (m, 2H, C H 2 Ph), 3.70 (s,

3H, OCH3), 3.78 (d, IH, OCHCO), 4.46 (m, IH , CHPO), 5.10 (m, 2H, C H 2(Z)), 5.27 (m,
IH, NH), 7.28 (m, 10H, 2Ph); 31P (101 MHz, CDC13)

8

25.1 25.2, 26.2, 26.4; FAB-MS

(NBA)/n/<? 491.1 (M-H)‘.

Z-Ala-Ala'P[(P02‘)0]-Phe-0Allyl (76):
According to procedure of 70, staring with Z-Ala-AlavF[(PHO)]-Phe-OAllyl 77 (214 mg,
0.42 mmol) to yield Z-Ala-Ala4/[(P 0 2 ')0]-P he-0A llyl 76 (140 mg, 63%). Analytical
HPLC: linear gradient over 65 min o f 65% solution A (0.25M ammonium acetate in
H 2 0 ) and 35% solution B (0.05M ammonium acetate in CH 3 CN-H20 4:1), flow rate 1
mL/min on a SUPELCOSIL LC 18S column; tR= 17.23min. *H NMR (250 MHz, CDC13)
8

1.07-1.38(m, 6 H, 2CH 3), 2.93-3.31 (m, 3H, CHCO+CH 2 Ph), 4.46 (2d, IH, CHPO),

4.65 (m, 2H, CH 2 CH=CH2), 5.09-5.31 (m, 3H, CH=CH 2 +CH2(Z)), 5.90 (m, IH,
CH=CH2), 7.28 (m, 10H, 2Ph); 3,P (101 MHz, CDC13)

8

24.9; FAB-MS (NBA)m/e (M-

H)' FAB-MS (NBA)m/e 516.6 (M -H)\

Z-Phe-Ala'P[(P02 )0]-Phe-0M e (73):
According to procedure o f 70, staring with Z-Phe-Ala'P[(PHO)]-Phe-OM e 82 (141 mg,
0.26 mmol) to yield Z-Phe-AlaxP [(P0 2 )0]-P he-0M e 73 (122 mg, 84%). lH NMR (250
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M Hz, CDCI3 )

8

1.07-1.33 (m, 3H, CH3), 3.03 (m, 2H, CH 2 Ph), 3.24 (t, IH,

(OCH(Bz)CO), 3,78 (s, 3H, C H 3), 4.22 (m, IH , CHCO), 4.46 (m, IH, CHPO), 5.08 (s,
2H, C H 2(Z)), 7.23 (m, 10H, 2Ph); 3lP (101 MHz, CDC13) 5 24.2, 24.6,24.8; FAB-MS m/e
567.5 (M -H )\
Z -P h e -A la 'F [(P 0 2 ')0]-P he-O A llyl (72):
According to procedure o f 70, staring with Z-Phe-Ala4/[(PHO)]-Phe-OAUy 83 (116 mg,
0.2 mmol) to yield Z-Phe-AlaxP [(P 0 2 )0]-Phe-0A llyl 72 (90 mg, 75 %).

Analytical

HPLC: linear gradient over 60 min o f 95% solution A (0.1M TEAA in H2 0 ) and 5%
solution B (0.02M TEAA in CH 3 CN-H20 4:1), flow rate 1 mL/min on a C-18 column; tR
= 23.5, 24.6 m in.lH NMR (300 MHz, CDC13)

8

1.28 (m, 3H, CH3), 3.04 (m, 4H,

2C H 2 Ph), 3.70 (m, IH, CHCO), 4.45 (m, IH, CHPO), 4.77 (m, 3H, OCHCO+CH=CH2),
5.31 (m, 4H, C H 2 (Z)+CH 2 CH=CH2), 5.89 (t, IH , CH=CH2), 7.26 (m, 15H, 3Ph); 3lP
(121 MHz, CD 3 OD)

8

22.4, 23.1,24.0; FAB-MS (NBA): m/e 595.5 (M-H)‘.

Z -P h e-V alT [(P 0 S * )0 ]-P h e-0 M e (71):
Z-Phe-V alvF[(PHO)0]-Phe-OM e 80 (0.23 g, 0.4 mmol) was taken up in dioxane (1 mL)
and treated with 5% sulfur in carbondisulfide-pyridine-TEA (9:9:1, 0.38 mL). After
stirring at room temperature for 5 h, the mixture was filtered then partitioned between
EtOAc and 2% KHSO 4 (10 mL each). The organic phase was washed successively with
w ater (15 mL), 5% NaHS 0 3 (15 mL) and saturated NaCl solution (15 mL), dried over
Na 2 S 0

4

and evaporated the solvent to give crude 71 (237 mg). The crude product was

purified by flash column chromatography (silica gel, MeOH-CHCb 1:9). Amino acid
analysis: 77%. Reverse phase analytical HPLC: linear gradient over 45 min of 100%
solution A (0.1% TFA in H 2 0 ) and 0% solution B (0.1% TFA in CH 3 CN-H 2 0 4:1), flow
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rate 1 mL/min over 40 min on a C4 column; tR = 34.1 min. Yield: 84 mg (37%). lH
NMR (250 MHz, CDC13) 5 0.86-1.04 (m, 6 H, 2CH3), 2.45 (m, IH, CH(CH3)2), 2.82 (m
IH, CHCO), 3.21 (m, 4H, 2CH 2 Ph), 3.59 (m, 3H, CH 3), 4.10 (2d, IH, CHPO), 4.43 (m,
IH, OCHCO), 4.89 (s, 2H, CH 2(Z)), 7.23 (m, 15H, 3Ph); 3lP (101 MHz, CD 3 OD)

8

76.4,

76.8; FAB-MS m/e 611.7 (M+H)+.
Z-Phe-V am (PO S-)0]-Phe-O A IIyl(51):
Z-Phe-VallP[(PHO)0]-Phe-0Allyl 81 (0.47 g, 0.77 mmol) was taken up in dioxane (1.5
mL) and treated with 5% Sulfur in Carbondisulfide-pyridine-TEA (9:9:1, 0.6 mL). After
stirring at room temperature for 5 h, the mixture was filtered then partitioned between
EtOAc and 2% KHSO 4 (20 mL each). The organic phase was washed successively with
water (30 mL), 5% N aH S0 3 (30 mL) and saturated NaCl solution (30 mL), dried over
Na 2 S 0 4 and evaporated to give crude Z-Phe-Val4/[(P0S')0]-Phe-0A llyl (510 mg). The
crude product was purified by flash column chromatography (silica gel, MeOH-CHCl3
1:12). Yield: 202 mg (41%). Analytical HPLC: linear gradient over 60 min of 65%
solution A (0.25M ammonium acetate in H 2 0 ) and 35% solution B (0.05M TEAA in
CH 3 CN-H20 4:1), flow rate 1 mL/min on a SUPELCOSIL LC 18S column; tR= 28.8min.
'H NMR (250 MHz, CD 3 OD)

8

0.74-1.04 (m, 6 H, 2CH3), 2.28 (m, IH, CH(CH3)2), 2.45

(m, IH, CHCO) 3.13 (m, 4H, 2CH 2 Ph), 4.08 (m, IH, CHPO), 4.51 (m, 3H, CH=CH2+
OCHCO), 4.97 (m, 2H, CH2(Z)), 5.22 (m, 2H, CH 2 CH=CH2), 5.88 (m, IH, CH=CH2)
7.25 (m, 15H, 3Ph); 31P (101 MHz, CDC13)

8

76.2, 76.5, 76.8; FAB-MS (GLY) m/e

638.6 (M+H)+.
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Z-Ala-AlavP[(P0S')0]-Phe-0M e (79):
According to procedure of 71, staring with Z-Ala-AlalF[(PHO)]-Phe-OMe 84 (97 mg, 0.2
mmol) to yield Z -A la-A la'F[(P0S)0]-Phe-0M e (95 mg, 94%). lH NMR (250 MHz,
CDC13) 5 1.14-1.43(m, 6 H, 2CH3), 2.95 (m, IH , CHCO), 3.12 (m, 2H, CH 2 Ph), 3.66 (d,
IH, OCHCO), 3.74 (s, 3H, OCH3), 4.46 (m, IH , CHPO), 5.09 (m, 2H, CH2(Z)), 7.28 (m,
10H, 2Ph); 3IP (101 MHz, CDCI3)

8

90.2, 90.4, 90.8, 91.2, 92.2; FAB-MS (NBA)m/e

506.9 (M -H)\

Z-Ala-Ala'P[(POS')0]-Phe-OAllyl (78):
According to procedure of 71, staring with Z-Ala-AlaxF[(PHO)]-Phe-OAllyl 85 (300 mg,
0.6 mmol) to yield Z-Ala-Ala4,[(P0S')0]-Phe-0A U yl 78 (262 mg, 82%). Analytical
HPLC: linear gradient over 60 min of 65% solution A (0.25M ammonium acetate in
H 2 0 ) and 35% solution B (0.05M ammonium acetate in CH 3 CN-H 2 0 4:1), flow rate 1
mL/min on a SUPELCOSIL LC 18S column; tR = 15.82min.
CDCI3 )

8

1.07-1.45(m,

6

‘H NMR (250 MHz,

H, 2CH3), 2.36-3.19 (m, 3H, CHCO+CH 2 Ph), 4.45 (2d, IH,

CHPO), 4.63 (m, 2H, CH 2 CH=CH2), 5.04-5.37 (m, 3H, CH=CH 2 +CH2(Z)), 5.85 (m, IH,
CH=CH2), 7.28 (m, 10H, 2Ph); 31P (101 MHz, CDC13)

8

76.3, 76.8, 77.0; FAB-MS

(NBA)m/fe 533.3 (M -H)\

Z-Phe-Ala'F[(POS)0]-Phe-OMe (75):
According to procedure of 71, staring with Z-Phe-AlavP[(PHO)]-Phe-OMe 82 (150 mg,
0.27 mmol) to yield Z-Phe-AlalP[(POS‘)0]-Phe-OM e 75 (119 mg, 76%). ‘H NMR (250
MHz, CDCI3 )

8

1.05-1.31 (m, 3H, C H 3), 3.05 (m, 4H, CH 2 Ph), 3.26 (t, IH,

(OCH(Bz)CO), 3,77 (s, 3H, C H 3), 4.25 (m, IH, CHCO), 4.47 (m, IH, CHPO), 5.08 (s,
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2H, CH 2 (z)), 7.23 (m , 10H, 2Ph); 3IP (101 MHz, CDC13) 8 74.8,75.3,76.1; FAB-MS m/e
585.4 (M -H)\

Z-Phe-Ala'F[(P0S')0]-Phe-0Allyl(74):
According to procedure of 71, staring with Z-Phe-Ala4/ [(PHO)]-Phe-OAlly 83 (116 mg,
0.2 mmol) to yield Z -Phe-A la^O W O l-P he-O A llyl 74

mg, 70 %). Analytical

(8 6

HPLC: linear gradient over 60 min of 65% solution A (0.25M ammonium acetate in
H 2 0 ) and 35% solution B (0.05M ammonium acetate in CH 3 CN-H 2 0 4:1), flow rate 1
mL/min on a SUPELCOSEL LC 18S column; tR = 15.91 min.

'H NMR (300 MHz,

CDCI3 ) 5 1.24 (m, 3H, CH3), 3.08 (m, 4H, 2CH 2 Ph), 3.68 (m, IH, CHCO), 4.47 (m, IH,
CHPO), 4.75 (m, 3H, OCHCO+CH=CH2), 5.35 (m, 4H, CH 2 ®+CH 2 CH=CH2), 5.88 (t,
IH, CH=CH2), 7.28 (m, 15H, 3Ph); 3,P (121 MHz, CD 3 OD)

8

76.7, 77.5, 78.3, 78.5;

FAB-MS (NBA): m /e 609.4 (M-H)\

Methyl ester cleavage reagent:71
The cleavage reagent lithium n-mecaptide in heamethylphosphoramide (HMPA) was
prepared by adding freshly n-propyl mercaptan (1 mL) to a suspension of ground lithium
hydride (0.3 g) in pre-purged HMPA (10 mL) under argon, stirred for I h followed by
nitration without contact with air. The reagent is stored at 0 °C without removal o f the
excess mercaptan. The concentration of mercaptide was 0.5-0.6 M.

General procedure for methyl ester cleavage:
The tripeptide phosphonate ester (0.22 mmol) was treated with 0.46 mmol lithium npropyl mercaptide in 1 mL o f hexamethyiphosphoramide (HMPA) and stirred at room
temperature for 25 °C for 2.5 h. The reaction mixture was diluted with water and washed
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six times with CHCI3 to remove HMPA, and the aqueous phase was lyophilized to yield
white powder. The crude product was purified by Sep-Pak purification:
The tripeptide analog sample (16 mg) was dissolved in 50 mM triethylammonium acetate
(TEAA) (1 mL, could be less). Two-connected Q g Sep-Pak cartridges were washed with
Water, MeOH, and 50 mM TEAA (5 mL each), then loaded with sample solution. Eluted
sample with 0%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, and 80% CH3CN in 50 mM
TEAA solution (5 mL each, 1 mL/fraction, 10 mL/min).

Lyophilized all fractions,

collected fractions with the same 3IP NMR signals.

Tetrakis(triphenylphosphine) palladium (0):78
The catalyst tetrakis(triphenylphosphine) palladium (0) was prepared according to
literature procedure . 7 3

The mixture o f palladium dichloride (200 mg, 1.1 mmol) and

triphenylphosphine (1.48 g, 5.6 mmol) in dimethyl sulfoxide (DMSO, 13.6 mL) was
heated to 140 °C. Hydrazine hydrate (0.22 mL, 4.5 mmol) was then rapidly added. The
dark solution was then immediately cooled with a water bath; crystallization begun to
occur at 125 °C. After the mixture has reached the room temperature it was filtered under
nitrogen on a funnel. The solid was washed with two 5 mL portions o f EtO H and two 5
mL portions of diethyl ether. The product was dried by passing a slow steam o f nitrogen
through the funnel overnight. The resulting yellow crystalline product was obtained
(1.19g, 91% yield).

General procedure for allyl ester cleavage:
The tripeptide phosphonate ester (0.14 mmol) was dissolved in dichloromethane (4 mL).
The solution was treated with morpholine (0.28 mmol) and Pd(P(Ph ) 3 ) 4 (0.014 mmol).
The mixture was stirred for 1 h, then added resin-bound PPh 3 (0.28 mmol) for 1 h to
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remove Pd. The solid was filtered off, and the solution was dried. The crude product
was purified by Sep-Pak purification.

General method for amino acid analysis
In a centrifugal tube was charged peptide sample (2 mg), isoleucine (10 nmol as
reference standard), HC1 (37%, 1 mL) and propionic acid (1 mL).

The solution was

heated to 160 °C for 1 h to hydrolyze, cooled to room temperature to lyophilize. The
residue was dissolved in HPLC grade w ater (250 mL). Then the solution (1 mL) was
lyophilized. The residue was dissolved in 200 pL water. 50 pL solution was injected
into amino acid analysis apparatus.

Z-Phe-VaPF[(P0 2')0]-Phe-OH (la):
Following the methyl ester cleavage procedure. Starting with Z-Phe-V al'P[(P0 2 ')0 ]P h eOallyl (49 mg, 0.08 mmol). Lyophilization yielded 32 mg o f a white powder. The crude
sample(16 mg) was loaded to Sep-Pak column and 13 mg oil-like triethylammonium salt
was obtained. Amino acid analysis: 37%; yield: 21%. Analytical HPLC: linear gradient
over 60 min o f 65% solution A (0.25M ammonium acetate in H 2 0 ) and 35% solution B
(0.05M ammonium acetate in CH 3 CN-H20 4:1), flow rate 1 mL/min over 60 min on a
SUPELCOSIL LC 18S column; tR = 9.98, 10,49min. *H NMR (250 MHz, CD 3 O D)

8

0.79-0.96 (m, 6 H, 2CH3), 2.19 (m, IH , C H (C H 3)2), 3.14 (m, 4H, 2CH 2 Ph), 4.04 (m, IH,
CHCO), 4.54 (m, IH, CHPO), 4.95 (m, 2H, C H 2(Z)), 7.21 (m, 15H, 3Ph); 3IP (101 MHz,
CD 3 OD) 5 18.1, 18.4; FAB-MS m/e 580.8 ((M -H)'); HRM S (FAB (M NBA)) m/e calc’d
for C 3 0 H 3 5 O 8 N2P ((M-H)'): 581.2053; found 581.2038.
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Z-Phe-VaI'F[(P0S )0]-P he-0H (lb):
Following the methyl ester cleavage procedure. Starting with Z-Phe-ValvF[(POS )0]PheOMe (61 mg, 0.1 mmol). Lyophilization yielded 48 mg o f a white powder. The crude
sample (16 mg) was loaded to Sep-Pak column and 15 mg oil-like triethylammonium salt
was obtained. Amino acid analysis: 49%; yield: 38%. Analytical HPLC: linear gradient
over 60 min of 65% solution A (0.25M ammonium acetate in H 2 0 ) and 35% solution B
(0.05M ammonium acetate in CH 3 CN-H20 4:1), flow rate 1 mL/min on a SUPELCOSIL
LC 18S column; tR= 9.75, 10.52min. lH NMR (250 MHz, CD 3 OD)

6

0.90-1.02 (m, 6 H,

2CH3), 2.20 (m, IH, C H (CH 3)2), 3.22 (m, 4H, 2CH 2 Ph), 4.15 (m, IH, CHCO), 4.56 (m,
IH, CHPO), 5.01 (m, 2H, C H 2(Z)), 7.20 (m, 15H, 3Ph); 3lP (101 MHz, CD 3 OD) 5 76.6;
FAB-MS m/e 596.7 ((M -H) ); HRMS (FAB (MNBA)) m/e calc’d for C 3 0 H 3 5 ON2PS (MH)*: 597.1824; found 597.1804.

Z-Phe-Ala'F[(P02)0]-Phe-O H (lc):
Following the allyl ester cleavage procedure. Starting with Z-Phe-Ala4/[(P 0 2 ‘)0]PheOAllyl (90 mg, 0.12 mmol). Lyophilization yielded 80 mg o f a white powder. The crude
sample (40 mg) was loaded to Sep-Pak column and 40 mg oil-like triethylammonium salt
was obtained. Analytical HPLC: linear gradient over 60 min of 95% solution A (0.1M
TEAA in H 2 0 ) and 5% solution B (0.02M TEAA in CH 3 CN-H20 4:1), flow rate 1
mL/min on a C-18 column; tR= 28.75, 29.33 min. *HNMR (250 MHz, CD 3 OD) 5 0.860.97 (m, 3H, C H 3), 2.07 (m, IH, CHCH3), 3.01 (m, 4H, 2CH 2 Ph), 4.14 (m, IH, CHCO),
4.52 (m, IH, CHPO), 5.03
CD 3 OD)

8

(m, 2H, CH2(Z)), 7.19 (m, 15H, 3Ph); 31P

(101 MHz,

19.0, 19.3, 22.2, 22.4; FAB-MS m/e 553.3 ((M-H) ); HRMS (FAB (MNBA))

m/e calc’d fo rC 2 8 H 3 l0 8 N 2P (M-H)' 553.1739; found 553.1757.
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Z -A la -A la W 0 2)O]-Phe-0H (le):
Following the allyl ester cleavage procedure. Starting with Z-Ala-AlalP[(P 0 2 ') 0 ]PheOallyl (32 mg, 0.062 mmol). Lyophilization yielded 27 mg of a white powder. The
crude sample was loaded to Sep-Pak column and 19 mg oil-like triethylammonium salt
was obtained. Analytical HPLC: linear gradient over 60 min of 95% solution A (0.1M
TEAA in H 2 O) and 5% solution B (0.05M TEAA in CH 3 CN-H 2 O 4:1), flow rate 1
mL/min over 60 min on a C-18 column; tR= 30.0 min. *H NMR (250 MHz, CD 3 OD)

8

1.41-1.43 (m, 6 H, 2CH3), 2.01 (m, IH, CHCH3), 3.27 (dd, 4H, 2CH 2 Ph), 3.65 (m, IH,
CHCO), 4.36 (m, IH, CHPO), 5.06 (m, 2H, C H 2 (z)), 7.25 (m, 10H, 2Ph); 3,P (101 MHz,
CD 3 OD)

8

19.0, 19.1, 19.2; FAB-MS m/e 476.9 (M-H)‘; HRMS (FAB (MNBA)) m/e

calc’d for C 2 2 H2 7 O 8 N 2 P ((M-H)'): 477.1426; found 477.1414.
Z-A la-Ala'P[(PO S')0]-Phe-O H (If):
Following the allyl ester cleavage procedure. Starting with Z-Ala-Ala4/[(P0S')0]PheOAllyl (74 mg, 0.14 mmol). Lyophilization yielded 54 mg of a white powder. The crude
sample (30 mg) was loaded to Sep-Pak column and 29 mg oil-like triethylammonium salt
was obtained. Analytical HPLC: linear gradient over 60 min of 95% solution A (0.1M
TEAA in H 2 O) and 5% solution B (0.05M TEAA in CH 3 CN-H 2 O 4:1), flow rate 1
mL/min over 60 min on a C-18 column; tR= 27.7 min. *H NMR (250 MHz, CD 3 OD)

8

1.31-1.36 (m, 6 H, 2CH3), 1.98 (m, IH , CHCH3), 3.16 (m, 4H, 2CH 2 Ph), 3.60 (m, IH,
CHCO), 4.14 (m, IH, CHPO), 5.08 (m, 2H, C H 2 ©), 7.26 (m, 10H, 2Ph); 3,P (101 MHz,
CD 3 OD) 8 76.5,76.8,77.7; FAB-MS m/e 493.8 (M-H)'.
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